WO2007084815A2 - Substituted thienopyrimidine kinase inhibitors - Google Patents

Substituted thienopyrimidine kinase inhibitors Download PDF

Info

Publication number
WO2007084815A2
WO2007084815A2 PCT/US2007/060296 US2007060296W WO2007084815A2 WO 2007084815 A2 WO2007084815 A2 WO 2007084815A2 US 2007060296 W US2007060296 W US 2007060296W WO 2007084815 A2 WO2007084815 A2 WO 2007084815A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino
compound
phenyl
salkyl
carboxylic acid
Prior art date
Application number
PCT/US2007/060296
Other languages
French (fr)
Other versions
WO2007084815A3 (en
Inventor
Peter J. Connolly
Steven A. Middleton
Stuart L. Emanuel
Ronghui Lin
Kathleen A. Battista
Gilles C. Bignan
Stuart Hayden
Sigmond G. Johnson
Niranjan B. Pandey
Mark T. Powell
Original Assignee
Janssen Pharmaceutica, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica, N.V. filed Critical Janssen Pharmaceutica, N.V.
Publication of WO2007084815A2 publication Critical patent/WO2007084815A2/en
Publication of WO2007084815A3 publication Critical patent/WO2007084815A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention is in the area of substituted thienopvrimidine compounds or forms thereof, their syntheses and their use as kinase inhibitors.
  • protein kinases are the largest set of structurally related phosphoryl transferases, have highly conserved structures and catalytic functions and may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, histidine and the like) and are responsible for the control of a wide variety of cellular signal transduction processes.
  • phosphorylate e.g., protein-tyrosine, protein-serine/threonine, histidine and the like
  • protein-tyrosine kinases include, but are not limited to, Irk, IGFR-I, Zap-70, Bmx, Btk, CHK (Csk homologous kinase), CSK (C-terminal Src Kinase), Ttk-1 , Src (c-Src, Lyn, Fyn, Lck, Syk, Hck, Yes, BIk, Fgr and Frk), Tec, Txk/Rlk, AbI, EGFR (EGFR- 1/ErbB-l, ErbB-2/NEU/HER-2, ErbB-3 and ErbB-4), FAK, FGFlR (also FGFRl or FGR-I), FGF2R (also FGR-2), MET (also Met-1 or c- MET), PDGFR ( ⁇ and ⁇ ), Tie-1, Tie-2 (also Tek-1 or Tek), VEGFRI (also FLT-I), VEGFR2 (also KDR),
  • Ark ATM (1-3), CamK (I-IV), CamKK, Chkl and 2 (Checkpoint kinases), CKI, CK2, Erk, IKK- 1 (also IKK-ALPHA or CHUK), IKK-2 (also IKK-BETA), Ilk, Jnk (1-3), LimK (1 and 2), MLK3Raf (A, B, and C), CDK (1-10), PKC (including all PKC subtypes), PIk (1-3), NIK, Pak (1-3), PDKl, PKR, RhoK, RIP, RIP-2, GSK3 ( ⁇ and ⁇ ), PKA, P38, Erk (1-3), PKB (including all PKB subtypes) (also AKT-I, AKT-2, AKT-3 or AKT3-1), IRAKI, FRK, SGK, TAKl or Tpl-2 (also COT).
  • Protein kinases play very important roles in the normal regulation of cell growth. However, as a result of dysrcgulation of the tyrosine kinases (receptor or non- receptor) or the ligands of the receptor tyrosine kinases, signaling can become deregulated, resulting in uncontrolled cell proliferation leading to cancer or a related disease, disorder or syndrome.
  • Protein kinases catalyze and regulate the process of phosphorylation, whereby the kinases covalently attach phosphate groups to proteins or lipid targets in response to a variety of extracellular signals: hormones, neurotransmitters, growth and differentiation factors, cell cycle events, environmental stresses, nutritional stresses and the like.
  • Phosphorylation modulates or regulates a variety of cellular processes such as proliferation, growth, differentiation, metabolism, apoptosis, motility, transcription, translation and other signaling processes.
  • Defective control of protein phosphorylation due to unregulated cellular mitosis, unregulated cell proliferation and upregulated kinase activity has been implicated in a number of diseases and disease conditions, such as osteoarthritis, rheumatoid arthritis, synovial pannus invasion in arthritis, multiple sclerosis, myasthenia gravis, diabetes mellitus, diabetic angiopathy, diabetic retinopathy, retinal vessel proliferation, inflammatory bowel disease, Crohns disease, ulcerative colitis, bone diseases, transplant or bone marrow transplant rejection, lupus, chronic pancreatitis, cachexia, septic shock, f ⁇ broproliferat ⁇ ve and different ⁇ ative skin diseases or disorders, central nervous system diseases, neurodegenerative diseases, disorders or conditions related to nerve damage and axon degeneration subsequent to
  • myasthenia gravis means a disease having the characteristic feature of easy fatigue of certain voluntary muscle groups on repeated use. Muscles of the face or upper trunk arc especially likely to be affected. In most and perhaps all cases, the disease is due to the development of autoantibodies against the acetylcholine receptor in neuromuscular junctions. Immunization of animals with this receptor protein leads to a disease with the features of myasthenia gravis.
  • pannus means a disease whereby vascularised granulation tissue rich in fibroblasts, lymphocytes and macrophages, derived from synovial tissue, overgrows the bearing surface of the joint in rheumatoid arthritis and is associated with the breakdown of the articular surface.
  • the tyrosine kinases can further be categorized by whether they are receptor tyrosine kinases or non-receptor tyrosine kinases.
  • the receptor tyrosine kinases span the cell membrane with a ligand interacting domain protruding from the cell, with a hydrophobic trans-membrane domain, and a cytoplasmic domain that contains the catalytic kinase domain and other regulatory sequences.
  • Non-receptor tyrosine kinases • are often myristylated or modified by the addition of other hydrophobic moieties that allow them to be anchored to the cell membrane.
  • the epidermal growth factor receptor (EGFR) tyrosine-kinase family includes the receptors EGFR (also referred to as EGFR-I or Erb-Bl), HER-2 (or ncu), EGFR3 and EGFR4.
  • EGFR epidermal Growth Factor
  • TGF- ⁇ Transforming Growth Factor- ⁇
  • HER-2 ligand hcrcgulin arc three of the ligands that bind to the EGFR receptors.
  • EGFR overexpression or mutation of one or more EGFR kinase family members has been commonly involved in cancer and other diseases characterized by uncontrolled or abnormal cell growth.
  • Deregulation of EGFR has also been associated with epidermoid tumors, head and neck tumors, breast tumors and tumors involving other major organs, such as the lungs and gastointestinal tract.
  • the clinically prevalent cancers related to EGFR include lung, gastric and head and neck cancer (Klijn JG 5 Bcrns PM, Schmitz PI and Fockcns JA;
  • the clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer a review on 5232 patients, Endocr. Rev., 1992, 13, 3-17; Salomon D and Gullick W; The erbB family of receptors and their ligands: Multiple targets for therapy, Signal, 2001, 2, 4-11).
  • Humphrey PA Kurpad SN, McLendon RE, Moscatello D 5 Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR and Bigner, DD; Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas, Cancer Res., 1995, 55, 3140-3148).
  • Diseases associated with increased EGFR expression include proliferative glomerulonephritis, diabetes-induced renal disease and chronic pancreatitis.
  • EGFR inhibitors tested in neurite outgrowth assays have activity in promoting neurite outgrowth in both cerebellar granule cells and dorsal root ganglion neurons, likely by acting directly on neurons to block neuronal inhibitory responses to myelin inhibitors, and thus an EGFR inhibitor may have potential use for promoting axon regeneration after brain and spinal cord injury (V. Koprivica, et al, EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans, Science, 2005, 310, 106).
  • HERl and HER2 overexpression has been implicated in a variety of cancers, such as bladder, breast, colorectal, endometrial, esophageal, gastric(stomach), glioma head and neck, lung (non-small cell lung cancer), ovarian, pancreatic, renal and prostate cancer.
  • HERl overexpression is found in breast, renal cell, lung, colorectal, head and neck, ovarian, pancreatic ⁇ glioma, bladder, esophageal, gastric, endometrial and cervical cancer tumors; in contrast, HER2 overexpression is found in esophageal, head and neck, lung, gastric, renal cell, breast, bladder, ovarian and colorectal, prostate and endometrial cancer tumors (Horizons in Cancer Therapeutics: From Bench to Bedside, Signal Transduction Inhibitors, 2001, 2(2), ISSN 1532-3048).
  • HER2 has been found to be responsible for these clinically prevalent cancers (Slamon DJ 5 Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL; Human breast cancer: Correlation of relapse and survival with amplification of HER-2/ncu oncogene, Science, 1987, 235, 177-82; Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al; Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 1989, 244, 707-712; Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS and Podrantz KC; HER-2/neu expression: A major prognostic factor in endometrial cancer, Gynecol. Oncol, 1992, 47, 179-85).
  • CMV Human cytomegalovirus
  • the human CMV uses the EGFR receptor to enter cells during infection, EGFR is autophosphorylated and the downstream signal transduction pathway components are activated; however, the EGFR specific inhibitor tyrphostin AG 1478 has been shown to reduce the viral load in cells that were infected in the presence of the tyrphostin (Wang X, et al., Nature, 24 July 2003, VoI 424, 456-461). Accordingly, potent EGFR selective inhibitors may be useful in anti-CMV therapy.
  • the Src family of tyrosine-kinases includes the sub-family proteins c-Src, Lyn, Fyn, Lck, Syk, Hck, Yes, BIk, Fgr and Frk. While various members of the c-Src family are important for normal cellular proliferation, their overexpression and overactivation can promote development of cancer (Yeatman TJ, Nature, June 2004, Vol. 4). For example, the Lyn kinase has been shown to be upregulated in hormone resistant prostate cancer.
  • CML chronic myeloid leukemia
  • the BCR-AbI fusion protein is a constitutively activated form of the AbI tyrosine kinase that drives uncontrolled growth leading to CML and many cases of adult acute lymphoblastic leukemia.
  • Gleevec is an inhibitor of AbI that has been successfully used to treat CML. However, Gleevec does not help patients in blast crisis because they carry mutant forms of BCR-AbI that no longer bind Gleevec.
  • Such Gleevec resistant CML cells are sensitive to a dual src/BCR-Abl inhibitor that binds and inhibits the mutant BCR-AbI and members of the src family (Shah, et al., Science, 16 July 2004, VoI 305, 399-401).
  • CML cells can also become resistant to treatment with the tyrosine kinase AbI inhibitor Gleevec in other ways.
  • CML K562 cells that become resistant to Gleevec minimize reliance on the BCR-AbI translocation for growth and instead upregulate the Lyn and Hck kinases, as demonstrated by expressing antisense Lyn in these cells, which reduced their rate of proliferation (Donato, et al., Blood, 15 Jan 2003, 101(2)).
  • c-Src and other Src family members arc also involved in cellular adhesion, invasion and motility of tumor cells.
  • small molecule inhibitors of the Src kinase family could offer new therapeutic opportunities for both leukemias and solid tumors.
  • Aurora kinases are highly conserved tyrosine kinases found in all organisms where they function to regulate microtubule dynamics during the M phase of the cell cycle and are essential for mitotic progression.
  • Aurora-A kinase associates with the centrosome around the pericentriolar material, as well as the microtubules at the bipolar mitotic-spindle poles and the midbody microtubules and plays a role in spindle formation and organization of the centrosome.
  • Aurora-B regulates chromosomal movement and cytokinesis and Aurora-C's biological function is not yet understood.
  • Aurora-A kinase is involved in centrosome separation, duplication and maturation as well as in bipolar spindle assembly and stability.
  • Aurora-A is overexpressed in a number of different human cancers and tumor cell lines. Overexpression of Aurora is sufficient to induce growth, in soft agar and transforms cells making them tumorigenic. Inhibition of Aurora activity results in centrosome/chromosome segregation defects leading to monopolar spindles and polyploidy which induces cell apoptosis in a variety of cancer cell lines and has suppressed tumor growth in vivo.
  • Angiogenesis plays a role in various processes including development of the vasculature, wound healing and maintenance of the female reproductive system.
  • Pathological angiogenesis is associated with disease states such as cancer, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis.
  • Solid-tumor cancers in particular, are dependent on angiogenesis for their growth.
  • the vascular endothelial growth factors (VEGFs) are mediators of both normal and pathologic angiogenesis. VEGF transmits signals into cells through their cognate receptors, which belong to the receptor tyrosine kinase (RTK) family of transmembrane receptors.
  • RTK receptor tyrosine kinase
  • receptors are tripartite, consisting of an extracellular ligand-binding domain, a transmembrane domain, which anchors the receptor in the membrane of the cell, and an intracellular tyrosine kinase domain.
  • RTKs One subfamily of RTKs comprises the receptors Fltl/VEGF-Rl and
  • KDR/Flkl /VEGF-R2 which bind VEGFs. Binding of the VEGF ligand to the receptor results in stimulation of the receptor tyrosine kinase activity and transduction of biological signals into the cell.
  • the KDR/Flkl/VEGF-R2 receptor mediates the biological activities of mitogenesis and proliferation of endothelial cells while the Fltl /VEGF-Rl receptor mediates functions such as endothelial cell adhesion.
  • potent small-molecule kinase inhibitors of one or more of the EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF kinase proteins and the like possessing anti-tumor cell proliferation activity are useful in treating or ameliorating a EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF kinase receptor mediated, angiogenesis-mediated or hyperproliferative disorder.
  • An example of the present invention includes using a compound of formula (I) as a protein kinase inhibitor.
  • An example of the present invention includes a method for using a compound of formula (T) as an inhibitor of a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF comprising contacting the protein kinase domain or receptor with the compound.
  • a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF
  • An example of the present invention includes a method for using a compound of formula (I) and forms, pharmaceutical compositions or medicaments thereof in treating, preventing or ameliorating a kinase mediated disorder.
  • the present invention is further direct to a method for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I) or a form thereof.
  • the present invention provides thienopyrimidine compounds of Formula (I):
  • L is selected from the group consisting of NH and O;
  • Ri is selected from the group consisting of aryl-Ra, heteroaryl-Ra, heterocyclyl-Ra, d-salkyl-Ci-salkoxy, Ci-galkyl-aryl-Ra Ci-salkyl-heteroaryl-Ra and Ci -salkyl-heterocyclyl-Ra;
  • Ra is one, two, three or four substitucnts each selected from the group consisting of hydrogen, halogen, Ci-salkyl, Ci.salkyl-halo, Ci-galkyl-hydroxy, Ci-salkoxy,
  • Ci.8alkoxy-h.alo Ci-salkoxy-hydroxy, amino, Ci-salkyl-amino, arnino-Cx-salkyl, Ci-8alkyl-amino-Ci- 8 alkyl, cyano, aryl-Rb, heteroaryl-Rb, heterocyclyl-Rb, Ci-salkyl-aryl-Rb, Ci -8 alkyl-heteroaryl-Rb, C ⁇ salkyl-heterocyclyl-Rb, Ci-salkyl-amino-aryl-Rb, Ci-sahcyl-amino-hetero aryl-Rb, Ci-salkyl-amino-heterocyclyl-Rb, Ci_ 8 alkyl-amino(Ci-8alkyl)-aryl-Rb,
  • R 2 is selected from the group consisting of aryl-Rc, heteroaryl-Rc and heterocyclyl-Rc;
  • Rc is one, two, three or four substituents each selected from the group consisting of hydrogen, cyano, halogen, C ⁇ alkyl, C ⁇ galkyl-halo, C ⁇ salkyl-hydroxy, Ci-8allcoxy, Ci-salkoxy-halo, Ci-salkoxy-hydroxy, amino, Ci-salkyl-amino, amino-Ci-galkyl, Ci_ 8 aLkyl-amino-Ci_ 8 alkyl, oxyaryl, oxyheteroaryl and amidoaryl; and
  • R 3 is selected from the group and amino.
  • An example of the present invention is a compound of Formula (I) and a form thereof wherein L is NH.
  • An example of the present invention is a compound of Formula (I) and a form thereof wherein L is O.
  • An example of the present invention is a compound of Formula (I) and a form thereof wherein Ri is selected from the group consisting of aryl-Ra, hctcroaryl-Ra, Ci-salkyl-Ci-galkoxy, Ci-salkyl-aryl-Ra and Ci-salkyl-heterocyclyl-Ra.
  • An example of the present invention is a compound of Formula (I) and a form thereof wherein
  • Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-galkoxy, Cj-galkoxy-halo, C ⁇ alkyl-arnino-d-salkyl, heterocyclyl-Rb, Ci ⁇ aliyl-heterocyclyl-Rb, Ci-saUcyl-amino ⁇ i-salky ⁇ -heterocyclyl-Rb, Ci-8aUsyl-amino(Ci-8alkyl)-Ci-8alkyl-heterocyclyl-Rb, oxyaryl-Rb and sulfonyl-amino-C i-galkyl-amino-Ci-sallcyl; and
  • Rb is Ci_ 8 alkyl.
  • An example of the present invention is a compound of Formula (I) and a form thereof wherein R 2 is selected from the group consisting of aryl-Rc and heteroatyl-Rc; and
  • Rc is one or two substituents each selected from the group consisting of hydrogen, halogen, Ci-salkyl, oxyaryl and amidoaryl.
  • the present invention is further directed to a compound of Formula (Ia):
  • R 1 is selected from the group consisting of aryl-Ra, heteroaryl-Ra, Ci-galkyl-aryl-Ra and Ci-galkyl-heterocyclyl-Ra;
  • Ra is one or two substituents each selected from the group consisting of hydrogen,
  • Rc is one or two substituents each selected from the group consisting of hydrogen, halogen, Ci. 8 alkyl, oxyaryl oxyheteroaryl and amidoaryl;
  • R3 is selected from the group consisting and amino.
  • An example of the present invention is a compound of Formula (Ia) and a form thereof wherein R 1 is selected from the group consisting of phenyl-Ra, pyridinyl-Ra, Ci-salkyl-phenyl-Ra, Ci-salkyl-piperidinyl-Ra and Ci-galkyl-pyrrolidinyl-Ra.
  • An example of the present invention is a compound of Formula (Ia) and a form thereof wherein
  • Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-salkoxy, Ci-galkoxy-halo, Ci-gaUcyl-amino-Ci-salkyl, morpholin-4-yl-Rb, piperazinyl-Rb, C 1- 8aikyl-morpholin-4-yl-Rb, Q-salkyl-piperidinyl-Rb,
  • the present invention is further directed to a compound of Formula (Ib):
  • Ra is one or two substituents each selected from the group consisting of hydrogen, Ci- ⁇ alkoxy, Ci-salkoxy-halo, Ci-salkyl-ammo-Ci-galkyl, heterocyclyl-Rb,
  • An example of the present invention is a compound of Formula (Ib) and a form thereof wherein
  • Ra is one or two substituents each selected from the group consisting of hydrogen, Ci -8 alkyl-amino-Ci-8alkyl, Ci_ 8 alkyl-heterocyclyl-Rb, Ci_saIkyl-amino(Ci-8alkyl)-heterocyclyl-Rb, Ci-8alkyl-amino(Ci-8alkyl)-Ci-8alkyl-heterocyclyl-Rb, oxyaryl-Rb and sulfonyl-amino-C i-salkyl-amino-C i-salkyl; and Rb is Ci_ 8 alkyl.
  • An example of the present invention is a compound of Formula (Ib) and a form thereof wherein Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-salkyl-amino-C i-salkyl, Q-salkyl-morpholin-4-yl-Rb, Ci.
  • Ri is selected from the group consisting of aryl-Ra, heteroaryl-Ra, Ci_ 8 alkyl-Ci -8 alkoxy,
  • Ci- 8 alkyl-aryl-Ra and Cj-salkyl-heterocyclyl-Ra; Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-8alkoxy, Ci_ 8 alkoxy-halo, Ci-salkyl-amino-Ci-salkyl, heterocyclyl-Rb, Ci-salkyl-heterocyclyl-Rb, Ci.salkyl-amino(Ci -8 alkyl)-heterocyclyl-Rb, Ci_ 8 alkyl-amino(Ci_ 8 alkyl)-C 1-8 alkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb and sulfonyl-amino-Ci.salkyl-arruno-Ci-salkyl; Rb is Ci -8 alkyl; and
  • Rci and Rc 2 is each one or two substituents each selected from the group consisting of hydrogen, halogen, Ci-salkyl, oxyaryl, oxyheteroaryl and amidoaryl.
  • An example of the present invention is a compound of Formula (Ic) and a form thereof wherein Ri is selected from the group consisting of phcnyl-Ra, pyridinyl-Ra, Ci- 8 alkyl-Ci_ 8 alkoxy, Ci -8 alkyl-phenyl-Ra, Ci_ 8 alkyl-morpholin-4-yl-Ra, Ci_ 8 alkyl-piperidinyl-Ra and Ci-salkyl-pyrrolidinyl-Ra.
  • An example of the present invention is a compound of Formula (Ic) and a form thereof wherein
  • Ra is one or two substituents each selected from the group consisting of hydrogen, Ci- ⁇ alkoxy, Ci-salkoxy-halo, Ci-salkyl-amino-Ci-salkyl, morpholin-4-yl-Rb, piperazinyl-Rb, Ci-salkyl-piperidinyl-Rb, Ci -8 aUkyl-amino(Ci-saU ⁇ yl)-pyranyl-Rb,
  • Ci_ 8 aUcyl-arnino(Ci-8aUcyl)-Ci- 8 aUcyl-tetrahydro-furanyl-Rb, oxyphenyl-Rb and and Rb is Ci-salkyl.
  • An example of the present invention is a compound of Formula (Tc) and a form thereof ⁇ herein Rc 1 and Rc 2 is each one or two substituents each selected from the group consisting of hydrogen, halogen, Q-salkyl, oxyphenyl and amidophenyl.
  • An example of the present invention is a compound of Formula (I) and a form thereof, wherein R 1 , L, R 2 and R 3 is selected from:
  • Compounds representative of a compound of Formula (I) or a form thereof include compounds and forms thereof selected from:
  • Bond lines drawn into a ting system from a substituent variable indicate that the substiruent may be attached to any of the substitutable ring atoms.
  • the following terms are intended to have the following definitions.
  • the definitions herein may specify that a chemical term has an indicated formula.
  • the particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term.
  • the scope of the per se definition of the term is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.
  • Ci-salkyl means a saturated aliphatic branched or straight-chain hydrocarbon radical or linking group having from 1 up to 8 carbon atoms in a linear or branched arrangement, wherein the radical is derived by the removal of one hydrogen atom from a carbon atom and the linking group is derived by the removal of one hydrogen atom from each of two carbon atoms in the chain.
  • Q-salkyl also includes a "Ci -6 alkyl” and "C ⁇ alkyl” radical or linking group having from 1 up to 6 carbon atoms and 1 up to 4 carbon atoms respectively, such as methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3- hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 1-octyl, 2-octyl, 3-octyl and the like.
  • Alkyl radicals or linking groups may be attached to a core molecule and farther substituted on any chain carbon atom when allowed by available valences.
  • Ci_8alkoxy means an alkyl radical or linking group having from 1 up to 8 carbon atoms in a linear or branched arrangement, wherein the radical or linking group is attached through an oxygen linking atom, as in the formula: -O-Ci- ⁇ alkyl.
  • Cj-galkoxy also includes a "Ci- ⁇ alkoxy” and radical or linking group having from 1 up to 6 carbon atoms and from 1 up to 4 carbon atoms respectively, such as methoxy, ethoxy, propoxy, butoxy and the like.
  • Alkoxy radicals or linking groups may be attached to a core molecule and further substituted on any chain carbon atom when allowed by available valences.
  • C3_i2cycloalkyl means a saturated or partially unsaturated cyclic hydrocarbon ring system radical.
  • C 3 -i 2 cycloalkyl also includes a Ca-scycloalkyl, Cs-iocycloalkyl, Cs- ⁇ cycloalkyl, Cs-scycloalkyl, Cs- ⁇ cycloalkyl, C 9 -i 3 cycloalkyl or benzofused-C 3 -;i 2 cycloalkyl ring system radical and the like, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, IH-indenyl, indanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, adamantanyl and the like.
  • C 3 _i 2 cycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • aryl means an unsaturated aromatic hydrocarbon ring system radical.
  • Aryl ring systems include phenyl, naphthalenyl, azulenyl, anthracenyl and the like. Examples of aryl in compounds representative of the present invention include phenyl or naphthalenyl.
  • Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • hetero when used as a prefix for a ring system, refers to the replacement of at least one carbon atom member in the ring system with a heteroatom selected from N, O, S, S(O), or SO 2 .
  • a hetero ring may have 1, 2, 3 or 4 carbon atom members replaced by a nitrogen atom.
  • a ring may have 1 , 2 or 3 nitrogen atom members and 1 oxygen or sulfur atom member.
  • a ring may have 1 oxygen or sulfur atom member.
  • up to two adjacent ring members may be heteroatoms, wherein one heteroatom is nitrogen and the other heteroatom is selected from N, S or O.
  • heterocyclyl means a saturated or partially unsaturated “hetero” ring system radical.
  • Heterocyclyl ring systems include azetidinyl, 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, 2-imidazolinyl (also referred to as 4,5- dihydro-lH-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, tetrazolyl, tetrazolidiny], piperidinyl, l,4-dioxanyl, morphoHnyl, 1 ,4-dithianyl, thiomorpholinyl, piperazinyl, azepanyl, hexahydro-l,4-diazepinyl, hexahydro-l,4-oxazepanyl
  • heterocyclyl also includes a benzofused-heterocyclyl ring system radical and the like, such as indolinyl (also referred to as 2,3-dihydro-indolyl), benzo[l,3]dioxolyl, 2,3-dihydro-l,4-benzodioxinyl, 2,3-dihydro-benzofuranyl, 1,2- dihydro-phthalazinyl and the like.
  • Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • hctcroaryl means an unsaturated aromatic "hetero" ring system radical.
  • Heteroaryl ring systems include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and the like.
  • Heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • heteroaryl also includes a benzofused-heteroaryl ring system radical and the like, such as indolizinyl, indolyl, azaindolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, azaindazolyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8- naphthyridinyl, pteridinyl and the like.
  • Benzofused-heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
  • Ci -8 alkoxy-halo means a radical of the formula: -0-Ci.salkyl-(halo)i.i 7 , wherein one or more halogen atoms may be substituted on Ci-8alkyl when allowed by available valences.
  • Ci-salkoxy-halo also includes a Ci_ 4 alkoxy-halo radical of the formula: -O-Ci- 4 alkyl-(halo) 1 _ 9 , such as rnonofluoromethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy and the like.
  • Ci -8 alkoxy-hydroxy means a radical wherein -O-C ⁇ salkyl is substituted on an available carbon chain atom with one or more hydroxy radicals.
  • Ci-salkyl-d-salkoxy means a radical of the formula: -Ci_ 8 alkyl-O-Ci_ 8 alkyl.
  • Ci_ 8 alkyl-ammo means a radical of the formula: -C 1-S aIlCyI-NH 2 .
  • Ci_8alkyl-amino-Ci_sallcyl means a radical of the formula: -Ci-salkyl-NH-Ci-galkyl or -Ci- 8 alkyl-N(Ci -8 alkyl) 2 .
  • Ci-salkyl-amino-aryl means a radical of the formula: -Ci-salkyl-NH-aryl.
  • the term means a radical of the formula: -Ci-galkyl-NH-heteroaryl.
  • Ci-salkyl-amino-heterocyclyl means a radical of the formula: -Ci-salkyl-NH-heterocyclyl.
  • Ci-saU-yl-amino(Ci_ 8 alkyl)-aryl means a radical of the formula:
  • C 1-8 alkyl-amino(Ci -8 ahcyl)-heteroaryl means a radical of the formula: -Ci-salkyl-NCd-salky ⁇ -heteroaryl.
  • C 1-8 alkyl-amino(Ci -8 alkyl)-heterocyclyl means a radical of the formula: -Ci_8alkyl-N(Ci- 8 alkyl)-heterocyclyl.
  • d-salkyl-amino-Ci-salkyl-aryl means a radical of the formula: -Ci-salkyl-NH-Ci-galkyl-aryl.
  • Ci-salkyl-amino-Ci-salkyl-heteroaryl means a radical of the formula: -Ci-galkyl-NH-Ci-galkyl-heteroatyl.
  • Ci.galkyl-amino-Ci.galkyl-heterocyclyl means a radical of the formula: -Cusalkyl-NH-Ci-salkyl-heterocyclyl.
  • Ci-salkyl-amino(Ci. 8 alkyl)-Ci-salkyl-aryl means a radical of the formula: -C i -8 alkyl-]N (Chalky Q-CVsalkyl-aryl.
  • Ci-galkyl-amino ⁇ i-galkyty-Ci-salkyl-heteroaryl means a radical of the formula: -Ci-8alkyl-N(C 1 . 8 alkyl)-C 1 _8alkyl-heteroaryl.
  • Ci -8 alkyl-arnino(Ci. 8 alkyl)-Ci -8 aLkyl-heterocyclyl means a radical of the formula: -Ci-8alkyl-N(Ci_ 8 alkyl)-C 1 -salkyl-hctcrocyclyl.
  • Ci. 8 alkyl-aryl means a radical of the formula: -Ci-salkyl-aryl.
  • Ci-galkyl-halo means a radical of the formula: -C 1 -SaUCyI-(IIaIo) 1 - I7 ., wherein one or more halogen atoms may be substituted on C ⁇ alkyl when allowed by available valences.
  • the term "Ci-salkyl-halo” also includes a radical of the formula: -Ci-4alkyl-(halo)i- 9 , such as monofluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl and the like.
  • Ci_galkyl-heteroaryl means a radical of the formula: -Ci-saLkyl-heteroaryl.
  • Ci-galkyl-heterocyclyl means a radical of the formula: -Ci-salkyl-heterocyclyl.
  • Ci-galkyl-hydroxy means a radical wherein Cj-salkyl is substituted on an available carbon chain atom with one or more hydroxy radicals.
  • amidoaryl means a radical of the formula: -NHC(O)-aryl.
  • amino means a radical of the formula: — ' NH2.
  • amino-Ci- 8 alkyl means a radical of the formula: -KfH-Ci-salkyl or -N(C 1-8 alkyl) 2 .
  • carbamoyl means a radical of the formula: -C(O)NH 2 .
  • carbamoyl-d-gallcyl means a radical of the formula: -C(O)NH-Ci. 8 alkyl or -C(O)N(Ci- 8 alkyl) 2 .
  • halogen or halo means the group chloro, bromo, fluoro or iodo.
  • oxyaryl means a radical of the formula: -O-aryl.
  • oxyheteroaryl means a radical of the formula: -O-heteroaryl.
  • sulfonyl-amino means a radical of the formula:
  • sulfonyl-amino-Ci.salkyl means a radical of the formula: -SO 2 -NH-Ci -8 a]kyl or -SO 2 -N(Ci_ 8 alkyl) 2 and the like.
  • sulfonyl-amino-Q-salkyl-amino means a radical of the formula: -SOz-NH-Ci-salkyl-NEb, -SO 2 -N(Ci- 8 alkyl)-Ci ⁇ alkyl-NH 2 or -SO 2 -N(C i -8 alkyl-NH 2 ) 2 and the like.
  • sulfonyl-a ⁇ no-C 1 _ 8 alJkyl-aimno-Ci-8alkyl means a radical of the formula: -SO 2 -NH-Ci.
  • sulfonyl-aryl means a radical of the formula: -S ⁇ 2-aryl.
  • sulfonyl-heteroaryl means a radical of the formula: -S0 2 -heteroaryl.
  • sulfonyl-heterocyclyl means a radical of the formula: -SO 2 -heterocyclyl.
  • substituted means the independent replacement of one or more hydrogen atoms within a radical with that amount of substirutents allowed by available valences.
  • form means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form.
  • the present invention encompasses all such compound forms and mixtures thereof.
  • isolated form means, in reference to compounds of the present invention, such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or ti'ans stereoisomer), a mixture of geometric isomers, and the like.
  • the present invention encompasses all such compound forms and mixtures thereof.
  • the compounds of the invention may be present in the form of pharmaceutically acceptable salts.
  • the "pharmaceutically acceptable salts" of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.
  • Suitable salt forms include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of an acid such as acetic acid, adipic acid, benzoic acid, carbonic acid, citric acid, fumaric acid, glycolic acid, hydrochloric acid, maleic acid, malonic acid, phosphoric acid, saccharinic acid, succinic acid, sulphuric acid, tartaric acid, trifluoro acetic acid and the like.
  • an acid such as acetic acid, adipic acid, benzoic acid, carbonic acid, citric acid, fumaric acid, glycolic acid, hydrochloric acid, maleic acid, malonic acid, phosphoric acid, saccharinic acid, succinic acid, sulphuri
  • suitable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligatids, e.g. quaternary ammonium salts.
  • alkali metal salts e.g. sodium or potassium salts
  • alkaline earth metal salts e.g. calcium or magnesium salts
  • suitable organic ligatids e.g. quaternary ammonium salts.
  • representative salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulphonate), carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, fumarate, gluconate, glutamate, glyconate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, malonate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, saccharinate, salicylate, stearate, sulfate, succinate, tartrate, tosylate, trichloroacetate, trifluoroacetate and the like.
  • Examples of salt forms of compounds representative of the present invention include the monohydrochlori.de salt.
  • any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry. ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis. 3 rd Edition, John Wiley & Sons, 1999.
  • the protecting groups may be removed at a convenient subsequent stage using methods known in the art.
  • the scope of the present invention encompasses all such protected compound forms and mixtures thereof.
  • the invention includes compounds of various isomers and mixtures thereof.
  • isomer refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (optical isomers).
  • optical isomer means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of 5 polarized light in different directions.
  • optical activity means the degree to which an optical isomer rotates the plane of polarized light.
  • racemate or “racemic mixture” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.
  • enantiomer means an isomer having a nonsuperimposable mirror image.
  • diastereomer means stereoisomers that are not enantiomers.
  • chiral means a molecule which, in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules which can be superimposed on their mirror images.
  • An example of an isolated form of an achiral mixture includes a dextrorotatory 0 enantiomer, wherein the mixture is substantially free of the levorotatory isomer.
  • substantially free means the levorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10 %, less than 5 %, less than 2 % or less than 1 % of the mixture according to the formula:
  • an example of an isolated form of an achiral mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer.
  • substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10 %, less than 5 %, less than 2 % or less than 1 % of the mixture according to the formula: ⁇ (mass dextrorotatory) 1 ⁇ n
  • geometric isomer means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system.
  • Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the “E” configuration, the substituents are on opposite sides in relationship to the carbon- carbon double bond. In the "Z” configuration, the substituents are oriented on the same side in relationship to the carbon-carbon double bond.
  • Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration.
  • the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring.
  • Compounds having a mixture of "cis” and “CTaUS” species are designated "cis/trans”.
  • the compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture.
  • Conventional resolution techniques include combining the free base (or free acid) of each isomer of an isomeric pair using an optically active acid (or base) to form an optically active salt (followed by fractional crystallization and regeneration of the free base), forming an ester or amide of each of the isomers of an isomeric pair by reaction with an appropriate chiral auxiliary (followed by fractional crystallization or chromatographic separation and removal of the chiral auxiliary), or separating an isomeric mixture of either an intermediate or a final product using various well known chromatographic methods.
  • compounds of the present invention may have one or more polymorph or amorphous crystalline forms and, as such, are intended to be included in the scope of the invention.
  • some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like) and, as such, are also intended to be encompassed within the scope of this invention..
  • the compounds of formula (I) are inhibitors of a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF, having an IC 5O (50% inhibition concentration) or an EC 50 (50% effective concentration) in a range of about 50 ⁇ M or less, of about 25 ⁇ M or less, of about 15 ⁇ M or less, of about 10 ⁇ M or less, of about 5 ⁇ M or less, of about 1 ⁇ M or less, of about 0.5 ⁇ M or less, of about 0.25 ⁇ M or less or of about 0.1 ⁇ M or less.
  • a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF
  • the present invention includes a compound of formula (I) and forms thereof as a protein kinase inhibitor, wherein the protein kinase is selected from EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF.
  • the present invention includes a prodrug form of a compound of formula (T) and forms thereof as a protein kinase inhibitor.
  • the present invention includes a metabolite form of a compound of formula (I) and forms thereof as a protein kinase inhibitor.
  • the present invention includes an isolated form of a compound of formula (1) and forms thereof as a protein kinase inhibitor.
  • the present invention includes a compound of formula (I) or a form thereof, wherein the compound is labeled with a ligand for use as a marker, and wherein the ligand is a radioligand selected from deuterium, tritium and the like.
  • the present invention includes use of a compound of formula (I) and forms thereof as an inhibitor of a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF comprising contacting the protein kinase domain or receptor with the compound.
  • a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF comprising contacting the protein kinase domain or receptor with the compound.
  • the present invention includes the use of a compound of formula (I) and forms thereof as a pharmaceutical composition, medicine or medicament for treating, preventing or ameliorating a kinase mediated disease, disorder or condition.
  • the present invention includes the use of a compound of formula (I) and forms thereof as a medicament.
  • the present invention includes the use of a compound of formula (I) and forms thereof in the manufacture of a medicament for treating, preventing or ameliorating a kinase mediated disease, disorder or condition.
  • the present invention includes the use of a prodrug of a compound of formula (I) and forms thereof as a pharmaceutical composition, medicine or medicament for treating, preventing or ameliorating a kinase mediated disease, disorder or condition.
  • the present invention includes the use of a prodrug of a compound of formula (I) and forms thereof as a medicament.
  • the present invention is directed to a method for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I) and forms thereof.
  • the method of the present invention further comprises administering to the subject an effective amount of a prodrug of a compound of formula (I) and forms thereof.
  • the method of the present invention further comprises treating, preventing or ameliorating a chronic or acute EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF mediated disease, disorder or condition.
  • the method of the present invention wherein the disease, disorder or condition is associated with increased or unregulated protein kinase activity, expression or signaling and the like in the subject.
  • the method of the present invention further comprises administering to the subject an effective amount of a compound of formula (I) as a pharmaceutical composition, medicine or medicament thereof.
  • the method of the present invention wherein the disease, disorder or condition is an EGFR kinase mediated head or brain cancer in the subject, and wherein the compound penetrates the blood brain barrier.
  • the method of the present invention further comprises treating or ameliorating nerve damage and promoting axon regeneration subsequent to a brain or spinal cord injury in the subject, wherein the compound is an EGFR inhibitor.
  • the method of the present invention further comprises treating, preventing or ameliorating viral infection by an EGFR kinase mediated cytomegalovirus in the subject.
  • chronic or acute protein kinase mediated disease, disorder or condition includes, and is not limited to diseases, disorders or conditions associated with unregulated kinase activity and conditions that accompany such activity.
  • unregulated protein kinase activity, expression or signaling refers to
  • unregulated cell proliferation refers to cell proliferation of one or more subset of cells in a multicellular organism resulting in harm (such as discomfort or decreased life expectancy) to the multicellular organism.
  • Tumor cells which result from unregulated cell proliferation use many mechanisms to enhance their survival and spread and often have high rates of proliferation because growth control signals that keep normal cells in check are defective. Many tumor cells secrete autocrine growth factors that increase proliferation rates or they induce other cells to secrete growth factors that they utilize.
  • a kinase inhibitor may affect one or more aspects of tumor survival mechanisms and thus be therapeutically useful.
  • a kinase inhibitor may not affect one particular tumor survival mechanism but may still be therapeutically useful by affecting tumor survival by an unknown or as yet unelucidated mechanism of action.
  • a compound of formula (I) or a form thereof is useful for treating, preventing or ameliorating diseases, disorders or conditions such as, without limitation, osteoarthritis, rheumatoid arthritis, synovial pannus invasion in arthritis, multiple sclerosis, myasthenia gravis, diabetes mellitus, diabetic angiopathy, diabetic retinopathy, retinal vessel proliferation, inflammatory bowel disease, Crohns disease, ulcerative colitis, bone diseases, transplant or bone marrow transplant rejection, lupus, chronic pancreatitis, cachexia, septic shock, fibroproliferative and differentiative skin diseases or disorders, central nervous system diseases, neurodegenerative diseases, disorders or conditions related to nerve damage and axon degeneration subsequent to a brain or spinal cord injury, acute or chronic cancer, occular diseases, viral infections, heart disease, lung or pulmonary diseases or kidney or renal diseases.
  • diseases, disorders or conditions such as, without limitation, osteoarthritis, rheumatoid arthritis, synovial pann
  • Certain diseases, disorders or conditions further include, without limitation, acute or chronic cancer selected from bladder cancer, brain, head or neck cancer, breast cancer, colorectal cancer, endometrial cancer, epidermoid cancer, esophageal cancer, gastric cancer, glioma cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, Kaposi's sarcoma, leukemia, lymphoma or papillocarcinoma; and, cancer-associated pathologies selected from abnormal cell proliferation, unregulated cell proliferation, tumor growth, tumor angiopathy, tumor angiogenesis, tumor vascularization or metastatic cancer cell invasion and migration.
  • acute or chronic cancer selected from bladder cancer, brain, head or neck cancer, breast cancer, colorectal cancer, endometrial cancer, epidermoid cancer, esophageal cancer, gastric cancer, glioma cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, Kaposi's sarcoma, leukemia,
  • Certain diseases, disorders or conditions further include, without limitation, fibroproliferative and differentiative skin diseases or disorders selected from papilloma formation, psoriasis, dermatitis, eczema, seborrhea or chcmothcrapy-induccd alopecia; central nervous system diseases selected from Alzheimer's disease, Parkinson's disease or depression; occular diseases selected from macular degeneration, diseases of the cornea or glaucoma; viral infections selected from mycotic infection, autoimmune disease or cytomegalovirus; heart disease selected from atherosclerosis, neointima formation or transplantation-induced vasculopathies such as arterial restenosis; lung or pulmonary diseases selected from allergic-asthma, lung fibrosis, pulmonary fibrosis or chronic obstructive pulmonary disorder; and, kidney or renal diseases selected from acute, subacute or chronic forms of glomerulonephritis or membranoproliferative glomerulonephritis
  • Certain HERl kinase mediated cancer includes, without limitation, bladder cancer, brain, head or neck cancer, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioma cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer or renal cell cancer.
  • Certain HER2 kinase mediated cancer includes, without limitation, bladder cancer, brain, head or neck cancer, breast cancer, colorectal cancer, gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, prostate cancer or renal cell cancer.
  • administering refers to a means for treating, ameliorating or preventing a disease, disorder or syndrome as described herein with a compound of formula (I) or a form thereof, which would obviously be included within the scope of the invention albeit not specifically disclosed for certain of said compounds.
  • Such methods include therapeutically or prophylactically administering an effective amount of compound of formula (T) or a form thereof at different times during the course of a therapy or concurrently in a combination form. Such methods further include administering an effective amount of said compound with one or more agents at different times during the course of a therapy or concurrently in a combination form.
  • prodrug means a compound of formula (1) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions.
  • Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the term "metabolite” means a prodrug form of a compound of formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a relatively less active functional derivative of said compound.
  • subject refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease or disorder or having a disease or disorder related to unregulated kinase activity.
  • an effective amount refers to that amount of a compound of formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting activation of unregulated kinase activity) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • the effective amount of said compound is from about 0.001 mg/kg/day to about 300 mg/kg/day. In another embodiment the effective amount of said compound is from about 0.01 mg/kg/day to about 30 mg/kg/day.
  • composition refers to a product containing a compound of formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from such combinations of the specified ingredients in the specified amounts.
  • the term “medicament” or “medicine” refers to a product containing a compound of formula (I) or a form thereof.
  • the present invention includes use of such a medicament for treating, preventing or ameliorating a chronic or acute kinase mediated disease, disorder or condition.
  • pharmaceutically acceptable refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention and that, when appropriately administered to an animal or a human, do not produce an adverse, allergic or other untoward reaction. Since both human use (clinical and over-the- counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use.
  • combination form refers to the use of a combination product comprising a compound of formula (I) or a form, pharmaceutical composition, medicine or medicament thereof and at least one therapeutic agent for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
  • the effective amount of a combination product for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition may be a reduced amount of either or both the compound or therapeutic agent compared to the effective amount of the compound or therapeutic agent otherwise recommended for treating, preventing or ameliorating the disease, disorder or condition. Therefore, it is contemplated that the compound is administered to the subject before, during or after the time the agent is administered.
  • chemotherapeutic agent refers to chemotherapeutic agents used to treat a kinase mediated cancer or antiviral agents used to treat cytomegalovirus.
  • Chemotherapeutic agents include and are not limited to anti-angiogenic agents, anti- tumor agents, cytotoxic agents, inhibitors of cell proliferation, radiation therapy and the like or a combination thereof.
  • treating, preventing or ameliorating refers, without limitation, to facilitating the eradication of, inhibiting the progression of or promoting stasis of a chronic or acute kinase mediated disease, disorder or condition.
  • the term "radiation therapy” refers to a therapy that comprises exposing the subject in need thereof to radiation.
  • the present invention includes a method for administering a compound of formula (I) or a form, pharmaceutical composition, medicine or medicament thereof in combination with radiation therapy. Procedures for administering such therapy are known to those skilled in the art. The appropriate scheme of radiation therapy will be similar to those already employed in clinical therapies wherein the radiation therapy is used alone or in combination with other chcmothcrapcutic agents.
  • the present invention includes a pharmaceutical composition comprising an admixture of a compound of formula (I) or a form thereof and one or more pharmaceutically acceptable excipients.
  • the present invention includes a process for making a pharmaceutical composition, medicine or medicament comprising mixing a compound of formula (I) or a form thereof and an optional pharmaceutically acceptable carrier.
  • the present invention includes a pharmaceutical composition, medicine or medicament resulting from the process of mixing a compound of formula (I) or a form thereof and an optional pharmaceutically acceptable carrier.
  • Contemplated processes include both conventional and unconventional pharmaceutical techniques.
  • Said pharmaceutical composition, medicine or medicament may take a wide variety of forms to effectuate mode of administration, wherein the mode includes, and is not limited to, intravenous (both bolus and infusion), oral, nasal, transdermal, topical with or without occlusion, and via injection intraperitoneally, subcutaneously, intramuscularly, intratumorally, intracerebrally or intracranially.
  • composition, medicine or medicament may be in a dosage unit such as a tablet, pill, capsule, powder, granule, sterile parenteral solution or suspension, mctcrcd aerosol or liquid spray, drop, ampoule, auto-injector device or suppository for such administration modes.
  • a dosage unit such as a tablet, pill, capsule, powder, granule, sterile parenteral solution or suspension, mctcrcd aerosol or liquid spray, drop, ampoule, auto-injector device or suppository for such administration modes.
  • compositions, medicines or medicaments suitable for oral administration include solid forms such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules and powders; and, liquid forms such as solutions, syrups, elixirs, emulsions and suspensions.
  • forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
  • the pharmaceutical composition, medicine or medicament may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • the dosage form (tablet, capsule, powder, injection, suppository, teaspoonful and the like) containing the pharmaceutical composition, medicine or medicament contains an effective amount of the active ingredient necessary to be therapeutically or prophylactically effective as described above.
  • the pharmaceutical composition, medicine or medicament may contain, from about 0.001 mg to about 5000 mg (preferably, from about 0.001 to about 500 mg) of a compound of formula (I) or a form thereof and may be constituted into any form suitable for the mode of administration selected for a subject in need.
  • An example of a contemplated effective amount for a pharmaceutical composition, medicine or medicament of the present invention may range from about 0.001 mg to about 300 mg/kg of body weight per day. In another example, the range is from about 0.01 mg/kg to about 30 mg/kg of body weight per day. In another example, the range is from about 0.003 to about 100 mg/kg of body weight per day. In another example, the range is from about 0.005 to about 15 mg/kg of body weight per day.
  • the pharmaceutical composition, medicine or medicament may be administered according to a dosage regimen of from about 1 to about 5 times per day.
  • the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula ( ⁇ ) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated.
  • Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed.
  • a representative compound, of formula (T) or a form thereof includes a compound selected from:
  • a representative compound of formula (I) or a form thereof includes a compound selected from:
  • a representative form of a compound of formula (I) includes a compound selected from:
  • Representative compounds of the present invention can be synthesized in accordance with the general synthetic schemes described below and are illustrated more particularly in the specific synthetic examples that follow.
  • the general schemes and specific examples are offered by way of illustration; the invention should not be construed as being limited by the chemical reactions and conditions expressed.
  • the methods for preparing the various starting materials used in the schemes and examples are well within the skill of persons versed in the art. No attempt has been made to optimize the yields obtained in any of the example reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.
  • Pyrimidin.e-4,6-diol Compound Al is refluxed in. a reagent solution (such as POCI 3 and the like in a solvent such as DMF and the like) to provide a 4,6-dichloro- pyrimidine-5-carbaldehyde Compound A2.
  • a reagent solution such as POCI 3 and the like in a solvent such as DMF and the like
  • a solution of Compound A2 (in an acidic solvent such as acetic acid) is reacted with a reagent solution (such as hydroxylamine hydrochloride and the like in a solvent such as 10% aqueous ethanol and the like) to provide a 4,6-dichloro-pyrimidme-5- carbonitrile Compound A3.
  • a reagent solution such as hydroxylamine hydrochloride and the like in a solvent such as 10% aqueous ethanol and the like
  • Compound A3 is refhixed in the presence of a reagent solution (such as thionyl chloride and the like, with or without a co-solvent such as toluene, 1,2-dichloroethane and the like) to provide a 4,6-dichloro-pyrimidine-5-carbonitrile Compound A4 (as described in Kloetzer,W. and Herberz,M., Reactions of 4,6-dichloro-5- formylpyrimidine, Monatsheftefuer Chemie, 1965, 96(5), 1573-8).
  • a reagent solution such as thionyl chloride and the like, with or without a co-solvent such as toluene, 1,2-dichloroethane and the like
  • a solution of Compound A5 (in a solvent such as THF, CH 3 CN, DMF, dioxane and the like; wherein L is as defined herein) is reacted with a solution of Compound A4 (in a solvent such as THF, CH 3 CN, DMF, dioxane and the like) in the presence of a base (such as DIPEA, Et 3 N and the like) to provide a Compound A6 (see also, ClarkJ. ct al.; J. Chem. Soc. Perkin Trans., 1976, 1, 1004-1007).
  • a base such as DIPEA, Et 3 N and the like
  • a solution of Compound A7 (in an organic base such as pyridine and the like, or in an organic base, such as TEA and the like containing a co-solvent such as THF, toluene and the like; wherein Rx is hydrogen or Ci-salkyl) is reacted with a solution of Compound A6 (in a solvent such as THF and the like) to provide a Compound A8.
  • an organic base such as pyridine and the like, or in an organic base, such as TEA and the like containing a co-solvent such as THF, toluene and the like; wherein Rx is hydrogen or Ci-salkyl
  • a solution of Compound A8 (in a solvent such as THF and the like) is reacted with a solution of a base (such as IM potassium t-butoxide, triethylamine and the like in a solvent such as THF and the like) to provide a Compound A3 (For methyl ester derivatives of compounds like Compound A9 see, Clark, J. and Hitiris, G., Heterocyclic studies. Part 43. Thieno[2,3-d:4,5-d']dipyrimidines, Journal of the Chemical Society, Perkin Transactions 1 : Organic and Bio-Organic Chemistry (1972-1999) (1984), (9), 2005-8).
  • a base such as IM potassium t-butoxide, triethylamine and the like in a solvent such as THF and the like
  • Compound A9 is reacted with a solution of Compound AlO (in a solvent such, as THF and the like) to provide a Compound All, representative of a compound of formula (I).
  • a solution of a commercially available Compound Bl (in a solvent such as DMF, dioxane and the like; wherein Rx is methyl) is reacted with a solution of a Compound A5 (in a solvent such as DMF, dioxane and the like) in the presence of a base (such as cesium carbonate and the like) to provide a Compound B2.
  • a base such as cesium carbonate and the like
  • a solution of Compound B2 (in a solvent such as THF, methanol, DMF, dioxane and the like) is reacted with a base (such as sodium hydroxide, lithium hydroxide, and the like), or a solution of the base (in a solvent such as THF, methanol, DMF, dioxane, water, and the like, or in a mixed solvent) to provide a Compound B3.
  • a base such as sodium hydroxide, lithium hydroxide, and the like
  • a solution of the base in a solvent such as THF, methanol, DMF, dioxane, water, and the like, or in a mixed solvent
  • Compound B3 is reacted with a solution of a Compound AlO (in a solvent such as DMF, THF and the like) to provide a Compound B4, representative of a compound of formula (I).
  • a Compound AlO in a solvent such as DMF, THF and the like
  • Examples 4-8 are intended as prophetic examples and are expected to demonstrate that said compounds are useful in treating, preventing or ameliorating a chronic or acute kinase mediated disease, disorder or condition as an inhibitor of the indicated kinase.
  • the EGFR kinase used was a fusion of Glutathione-S-Transferase (GST) and a PCR amplified intracellular portion of EGFR (NM_005228).
  • the intracellular portion of EGFR started at nucleotide 2189 (corresponding to amino acid 667) and ended at the termination codon.
  • the portion was PCR amplified with primers that added the lambda attB sequences to each end, recombined into an entry vector, then into a GST destination vector (as described in Gateway Technologies Manual by Tnvitrogen Corporation. , Carlsbad, California).
  • the destination vector was recombined in the DHlOBAC strain of bacteria to produce a bacmid.
  • the bacmid was transfected into Sf 9 cells and the supernatant containing the baculovirus was collected.
  • the GSTEGFR protein was purified using large cultures of Sf 9 cells infected with stock virus. After an appropriate period of time, the cells were collected and lysed. The GSTEGFR was then purified from the lysate on Glutathione-Sepharose columns (as described by Amersham Biosciences, Buckinghamshire, United Kingdom).
  • the EGFR substrate was prepared by biotinylating polyGluTyr (128 mg)
  • a mixture of a 1OX kinase buffer (500 mM Tris at pH 8.0, 100 mM Magnesium Chloride and 1 mM Sodium Vanadate), DTT (1 mM final from 500 mM stock), ATP (5 uM final from 10 mM stock), biotinylated polyGluTyr (10 ⁇ g/ ⁇ L stock), ⁇ - 33 P ATP (10 ⁇ Ci/ ⁇ L stock) and water was added to each well (90 ⁇ L/well) of a Streptavidin Flashplate (Perkin Elmer, Wellesley, MA).
  • 1OX kinase buffer 500 mM Tris at pH 8.0, 100 mM Magnesium Chloride and 1 mM Sodium Vanadate
  • DTT (1 mM final from 500 mM stock
  • ATP 5 uM final from 10 mM stock
  • biotinylated polyGluTyr (10 ⁇ g/ ⁇ L stock
  • ⁇ - 33 P ATP 10
  • Test compound in 100% DMSO (2 ⁇ L) was added to the appropriate wells.
  • Diluted GSTEGFR (1 :300 dilution in 50 mM Tris at pH 8.0 and 0.1% bovine scrum albumin) (10 ⁇ L) was added to the wells to initiate the reactions.
  • the plates were incubated at 30 0 C for 1 hr with shaking. The reacted contents were removed and the plates were sequentially washed three times with a IX PBS stop buffer (300 ⁇ L without Magnesium and Calcium) and 100 mM EDTA. After the final wash, the same stop buffer (200 ⁇ L) was added to the wells. The plates were then sealed and read on the TopCount scintillation counter.
  • Test compounds were assayed in triplicate at 16 concentrations at half-log dilutions starting at 200 uM. A maximum and minimum signal for the assay was determined on each plate. The percent inhibition of a test compound was calculated according to the formula (max signal - test compound)
  • the IC50 was derived by graphing percent inhibition against the log of the concentrations tested for a given compound. The IC50 results are shown in Table 1. For those compounds without an TC 50 , the percent inhibition results are shown at a test concentration of 2 ⁇ M.
  • a kinase reaction mixture was prepared containing 50 mM Tris-HCl at pH 8, 10 mM MgCl 2 , 0.1 mM Na 3 PO 4 , 1 mM DTT, 10 ⁇ M ATP, 0.025 ⁇ M biotinylated histone- Hl peptide substrate and 0.2 ⁇ Curies per well 33P - ⁇ -ATP (2000-3000 Ci/mmol).
  • 70 ⁇ L of the kinase reaction mixture was dispensed into the well of a Strcptavidin FlashPlatc. Test compound stock in 100% DMSO (1 ⁇ L) was added to the wells resulting in a final concentration of 1% DMSO in the reaction with a 100 ⁇ L final reaction volume.
  • the VEGF -R2 enzyme is a fusion protein containing a polyhistidine tag at the N terminus followed by amino acids 786 to 1343 of the rat VEGF-R2 kinase domain (Accession number U93306).
  • the assay used 150 ng of the N-terminal biotinylated peptide biotin-KHKEXAEGSAYEEV-amide (VEGF-R2) per well.
  • Aurora-A is a fusion protein containing a polyhistidine tag at the N terminus followed by the full length protein encoding the murine Aurora-A (Accession number GB BC014711) expressed and purified from sf9 insect cells.
  • the assay used 400 ng of the N-terminal biotinylated peptide b ⁇ otin-GRTGRRNS ⁇ -amide (Aurora-A) per well.
  • the IC50 was derived according to the procedure described in Example 1.
  • HER-2 kinase was purified at Proqinase (Freiburg, Germany) from a construct that consisted of a fusion of GST (Glutathione-S-Transferase), HIS6-Thrombin and the nucleotides encoding amino acids 679 to 1255 of HER-2.
  • a mixture of a 1OX kinase reaction buffer (600 mM Hepes at pH 7.5, 30 mM Magnesium Chloride, 0.03 mM Sodium Vanadate and 500 ⁇ ig/mL PEG 20,000), DTT (1.2 mM final from a 10 mM stock), ATP (1 ⁇ M from a 10 mM stock), biotinylated polyGluTyr (1.5 ng/ ⁇ L final from stock of 1 ⁇ g/ ⁇ L prepared by Upstate Biotechnologies, Lake Placid, New York), Manganese Chloride (3 mM final from a 1 M stock), ⁇ - 33 P-ATP (10 ⁇ Ci/ ⁇ L stock) and water (70 ⁇ L/well) was added to each well of a Streptavidin Flashplate (Cat. # SMP 103, NEN, Boston, MA). Test compound stock (1 ⁇ L) was added to the appropriate wells. Diluted
  • GSTHER2 kinase (6.7 ng/ ⁇ L diluted into 50 mM Tris-HCl at pH 8.0 and 0.1% bovine serum albumin) (30 ⁇ L) was added (total volume of 200 ng/well) to initiate the reactions.
  • the reaction plates were incubated at 30 0 C for 1 hr. The reaction was terminated by aspirating the reaction mixture from the plate wells and washing the wells three times with a 1 X PBS stop buffer (300 ⁇ L) and 100 mM EDTA. After the final wash, the same stop buffer (200 ⁇ L) was again added to the wells. The plates were then sealed and read on the TopCount scintillation counter.
  • the IC50 was derived according to the procedure described in Example 1. Table 3
  • EXAMPLE 4 c-Src Kinase Assay A mixture of a 1 OX kinase buffer (80 mM MOPS at pH 7.0, 2 mM EDTA and
  • Diluted c-Src kinase (human) (Upstate Biotechnology, Lake Placid, New York) (diluted in a buffer consisting of 20 mM MOPS at pH 7.0, 1 mM EDTA, ⁇ -mercaptoethanol (0.1%), Brij-35 (0.01%), glycerol (5 %), and 1 mg/mL bovine serum albumin) (2.5 ⁇ L) is added to the wells to initiate the reactions. The reaction plates are incubated at 30 0 C for 40 min. The reaction is terminated by the addition of a 3% phosphoric acid solution (5 ⁇ L). The reaction product (10 ⁇ L) is spotted onto a P30 filtermat and washed for 5 minutes in phosphoric acid (75 mM).
  • EXAMPLE 5 Lyn Kinase Assay A mixture of a 1 OX kinase buffer (50OmM MOPS at pH 7.5 , 1 mM EGTA, 1 mM Sodium Vanadate, 1% ⁇ -mercaptoethanol and 100 rnM Magnesium Acetate), ATP (5 ⁇ M final from a 10 mM stock), polyGluTyr (0.1 mg/mL final from a 1 mg/mL stock), 7- 33 P ATP (10 ⁇ Ci/ ⁇ L stock) and water (20 ⁇ L/well) was added to each well of a Streptavidin Flashplate. Test compound in 100% DMSO (0.5 ⁇ L) was added to the appropriate wells.
  • Diluted Lyn kinase human (Upstate Biotechnology, Lake Placid, New York) (diluted in a buffer consisting of 50 mM Tris at pH 7.5, 0.1 mM EGTA, Sodium Vanadate (0.1 mM), ⁇ -mercaptoethanol (0.1%) and 1 mg/mL bovine serum albumin) (2.5 ⁇ L) was added to the wells to initiate the reactions.
  • the reaction plates were incubated at 30 0 C for 40 min. The reaction was terminated by the addition of a 3% phosphoric acid solution (5 ⁇ L).
  • the reaction product (10 ⁇ L) was spotted onto a P30 filtermat and washed for 5 minutes in phosphoric acid (75 mM).
  • a mixture of a 1OX kinase buffer (80 mM MOPS at pH 7.0, 2 mM EDTA and 100 mM Magnesium Acetate), ATP (5 ⁇ M final from a 10 mM stock), a peptide EAIYAAPFAKKK (50 ⁇ M final from a 0.5 mM stock), ⁇ - 33 P ATP (10 ⁇ Ci/ ⁇ L stock) and water is added to each well (20 ⁇ L/well) of a Streptavidin Flashplate. Test compound in 100% DMSO (0.5 ⁇ L) is added to the appropriate wells.
  • Diluted c-Abl kinase (human) (Upstate Biotechnology, Lake Placid, New York) (diluted in a buffer consisting of 20 mM MOPS at pH 7.0, 1 mM EDTA, ⁇ -mercaptoethanol (0.1%), Brij-35 (0.01%), glycerol (5 %) and 1 mg/ml bovine serum albumin) (2.5 ⁇ L) is added to the wells to initiate the reactions. The reaction plates are incubated at 30 0 C for 40 min. The reaction is terminated by the addition of a 3% phosphoric acid solution (5 ⁇ L). The reaction product (10 ⁇ L) is spotted onto a P30 filtermat and is washed for 5 minutes in phosphoric acid (75 mM).
  • the wash sequence is repeated two more times and is followed with one final wash in methanol.
  • the plates are then dried, sealed and read on the TopCount scintillation counter after 30 ⁇ L scintillation fluid is added.
  • the ICso is derived according to the procedure described in Example 1.
  • test compound The ability of a test compound to inhibit unregulated cell proliferation was determined by measuring incorporation of ' 4 C-labelled thymidine into newly synthesized DNA within cell lines derived from carcinomas originating from several tissues. Accordingly, the anti-proliferative effect of a compound on cells with a variety of phenotypes may be determined.
  • Carcinoma cell lines include those such as HeLa cervical adenocarcinoma (American Type Culture Collection (ATCC), Virginia, Cat. #CCL-2), A375 malignant melanoma (ATCC CRL-1619), SK-OV-3 ovarian adenocarcinoma (ATCC HTB-77), HCT-116 colon carcinoma (CCL-247), PC-3 prostate adenocarcinoma (ATCC CRL- 1435), and MDA-MB-231 (Xenogen Corp.)
  • the carcinoma cells were trypsinizcd and counted.
  • the cells (3000-8000 count) were added to each well of a 96-well CytoStar tissue culture treated scintillating microplate (Amersham #RPNQ0160) in complete medium (100 ⁇ L) and the plate was then incubated in complete medium for 24 hrs at 37 0 C in an inert atmosphere containing 5% CO2.
  • Test compound (1 ⁇ L) in 100% DMSO was added to the plate test-wells with DMSO only added to control-wells. The plate was incubated in complete medium for a second 24 hr period at 37 0 C in an atmosphere containing 5% CO 2 .
  • the ability of a test compound to inhibit unregulated growth of human tumor cells in vivo may be evaluated by implanting human tumor cells into the hindflank of athymic mice, administering a test compound and then quantifying any change in tumor size.
  • Human epidermoid A431 carcinoma cells (10 6 count) are implanted subcutaneously into the hindflank of female athymic mice (Charles River) and allowed to grow for 6-10 days. After a measurable tumor is established (as determined by baseline caliper measurement), the animal is administered an oral dose of the test compound (in 10% solutol) daily for a period of 30 days. Tumor size is measured every five days and the degree of inhibition is determined by comparing drug-treated animals to vehicle-treated animals.
  • Variations of this method are intended to include intraperitoneal injection or intravenous infusion as the route of administration and administration of the test compound either alone or in a combination therapy.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention is directed to thienopyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.

Description

SUBSTITUTED THTENOPYRTMΪDTNE KINASE TNHTBTTORS
CROSS REFERENCE TO RELATED APPLICATIONS This present application claims benefit of U.S. Provisional Patent Application Serial No. 60/760,234, filed January 19, 2006, which is incorporated herein by reference in its entirety and for all purposes.
FIELD OF THE INVENTION
The present invention is in the area of substituted thienopvrimidine compounds or forms thereof, their syntheses and their use as kinase inhibitors. BACKGROUND OF TBE INVENTION
In general, protein kinases are the largest set of structurally related phosphoryl transferases, have highly conserved structures and catalytic functions and may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, histidine and the like) and are responsible for the control of a wide variety of cellular signal transduction processes.
Examples of protein-tyrosine kinases include, but are not limited to, Irk, IGFR-I, Zap-70, Bmx, Btk, CHK (Csk homologous kinase), CSK (C-terminal Src Kinase), Ttk-1 , Src (c-Src, Lyn, Fyn, Lck, Syk, Hck, Yes, BIk, Fgr and Frk), Tec, Txk/Rlk, AbI, EGFR (EGFR- 1/ErbB-l, ErbB-2/NEU/HER-2, ErbB-3 and ErbB-4), FAK, FGFlR (also FGFRl or FGR-I), FGF2R (also FGR-2), MET (also Met-1 or c- MET), PDGFR (α and β), Tie-1, Tie-2 (also Tek-1 or Tek), VEGFRI (also FLT-I), VEGFR2 (also KDR), FLT-3, FLT- 4, c-KIT, JAKl, JAK2, JAK3, TYK2, LOK, RET, TRKA, PYK2, ALK (Anaplastic Lymphoma Kinase), EPHA (1-8), EPHB (1-6), RON, Fes, Fer or EPHB4 (also EPHB4-1). Examples of protein-serine/threonine kinases include, but are not limited to,
Ark, ATM (1-3), CamK (I-IV), CamKK, Chkl and 2 (Checkpoint kinases), CKI, CK2, Erk, IKK- 1 (also IKK-ALPHA or CHUK), IKK-2 (also IKK-BETA), Ilk, Jnk (1-3), LimK (1 and 2), MLK3Raf (A, B, and C), CDK (1-10), PKC (including all PKC subtypes), PIk (1-3), NIK, Pak (1-3), PDKl, PKR, RhoK, RIP, RIP-2, GSK3 (α and β), PKA, P38, Erk (1-3), PKB (including all PKB subtypes) (also AKT-I, AKT-2, AKT-3 or AKT3-1), IRAKI, FRK, SGK, TAKl or Tpl-2 (also COT).
Protein kinases play very important roles in the normal regulation of cell growth. However, as a result of dysrcgulation of the tyrosine kinases (receptor or non- receptor) or the ligands of the receptor tyrosine kinases, signaling can become deregulated, resulting in uncontrolled cell proliferation leading to cancer or a related disease, disorder or syndrome.
Protein kinases catalyze and regulate the process of phosphorylation, whereby the kinases covalently attach phosphate groups to proteins or lipid targets in response to a variety of extracellular signals: hormones, neurotransmitters, growth and differentiation factors, cell cycle events, environmental stresses, nutritional stresses and the like.
Phosphorylation modulates or regulates a variety of cellular processes such as proliferation, growth, differentiation, metabolism, apoptosis, motility, transcription, translation and other signaling processes. Defective control of protein phosphorylation due to unregulated cellular mitosis, unregulated cell proliferation and upregulated kinase activity has been implicated in a number of diseases and disease conditions, such as osteoarthritis, rheumatoid arthritis, synovial pannus invasion in arthritis, multiple sclerosis, myasthenia gravis, diabetes mellitus, diabetic angiopathy, diabetic retinopathy, retinal vessel proliferation, inflammatory bowel disease, Crohns disease, ulcerative colitis, bone diseases, transplant or bone marrow transplant rejection, lupus, chronic pancreatitis, cachexia, septic shock, fϊbroproliferatϊve and differentϊative skin diseases or disorders, central nervous system diseases, neurodegenerative diseases, disorders or conditions related to nerve damage and axon degeneration subsequent to a brain or spinal cord injury, acute or chronic cancer, occular diseases, viral infections, heart disease, lung or pulmonary diseases or kidney or renal diseases. Therefore, kinase inhibitors have potential use as therapeutic agents.
The term "myasthenia gravis" means a disease having the characteristic feature of easy fatigue of certain voluntary muscle groups on repeated use. Muscles of the face or upper trunk arc especially likely to be affected. In most and perhaps all cases, the disease is due to the development of autoantibodies against the acetylcholine receptor in neuromuscular junctions. Immunization of animals with this receptor protein leads to a disease with the features of myasthenia gravis. In reference to "synovial pannus invasion in arthritis," the term "pannus" means a disease whereby vascularised granulation tissue rich in fibroblasts, lymphocytes and macrophages, derived from synovial tissue, overgrows the bearing surface of the joint in rheumatoid arthritis and is associated with the breakdown of the articular surface. The tyrosine kinases can further be categorized by whether they are receptor tyrosine kinases or non-receptor tyrosine kinases. The receptor tyrosine kinases span the cell membrane with a ligand interacting domain protruding from the cell, with a hydrophobic trans-membrane domain, and a cytoplasmic domain that contains the catalytic kinase domain and other regulatory sequences. Non-receptor tyrosine kinases • are often myristylated or modified by the addition of other hydrophobic moieties that allow them to be anchored to the cell membrane.
The epidermal growth factor receptor (EGFR) tyrosine-kinase family includes the receptors EGFR (also referred to as EGFR-I or Erb-Bl), HER-2 (or ncu), EGFR3 and EGFR4. Epidermal Growth Factor (EGF), Transforming Growth Factor-α (TGF- α) and the HER-2 ligand hcrcgulin arc three of the ligands that bind to the EGFR receptors.
For example, EGFR overexpression or mutation of one or more EGFR kinase family members has been commonly involved in cancer and other diseases characterized by uncontrolled or abnormal cell growth. Deregulation of EGFR has also been associated with epidermoid tumors, head and neck tumors, breast tumors and tumors involving other major organs, such as the lungs and gastointestinal tract. The clinically prevalent cancers related to EGFR include lung, gastric and head and neck cancer (Klijn JG5 Bcrns PM, Schmitz PI and Fockcns JA; The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients, Endocr. Rev., 1992, 13, 3-17; Salomon D and Gullick W; The erbB family of receptors and their ligands: Multiple targets for therapy, Signal, 2001, 2, 4-11).
In treating cancers of the head such as brain cancers and the like, the ability of small molecule EGFR inhibitors to penetrate the blood, brain barrier could have therapeutic advantages since EGFR is often overexpressed in primary brain tumors and also in breast and non-small cell lung carcinomas that frequently metastasize to the brain (Eckstrand AJ, Sugawa N, James CD and Collins VP; Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails, Prυc. Acad. Natl. Sd. USA, 1992, 89, 4309-4313; and, Wickstrand CJ, Hale LP, Batra SK, Hill ML,
Humphrey PA, Kurpad SN, McLendon RE, Moscatello D5 Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR and Bigner, DD; Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas, Cancer Res., 1995, 55, 3140-3148).
Diseases associated with increased EGFR expression include proliferative glomerulonephritis, diabetes-induced renal disease and chronic pancreatitis.
EGFR inhibitors tested in neurite outgrowth assays have activity in promoting neurite outgrowth in both cerebellar granule cells and dorsal root ganglion neurons, likely by acting directly on neurons to block neuronal inhibitory responses to myelin inhibitors, and thus an EGFR inhibitor may have potential use for promoting axon regeneration after brain and spinal cord injury (V. Koprivica, et al, EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans, Science, 2005, 310, 106).
HERl and HER2 overexpression has been implicated in a variety of cancers, such as bladder, breast, colorectal, endometrial, esophageal, gastric(stomach), glioma head and neck, lung (non-small cell lung cancer), ovarian, pancreatic, renal and prostate cancer. Comparing the overexpression of HERl and HER2 in tumors, according to order of prevalence, HERl overexpression is found in breast, renal cell, lung, colorectal, head and neck, ovarian, pancreatic^ glioma, bladder, esophageal, gastric, endometrial and cervical cancer tumors; in contrast, HER2 overexpression is found in esophageal, head and neck, lung, gastric, renal cell, breast, bladder, ovarian and colorectal, prostate and endometrial cancer tumors (Horizons in Cancer Therapeutics: From Bench to Bedside, Signal Transduction Inhibitors, 2001, 2(2), ISSN 1532-3048). While the degree of HER2 overexpression in breast and ovarian cancer is not as great as in some other cancers, HER2 has been found to be responsible for these clinically prevalent cancers (Slamon DJ5 Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL; Human breast cancer: Correlation of relapse and survival with amplification of HER-2/ncu oncogene, Science, 1987, 235, 177-82; Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al; Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 1989, 244, 707-712; Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS and Podrantz KC; HER-2/neu expression: A major prognostic factor in endometrial cancer, Gynecol. Oncol, 1992, 47, 179-85).
Furthermore, patients with HER-2 overexpressing breast cancer frequently experience metastases to the brain (Kirsch DG and Hochberg FH; Targeting HER-2 in brain metastases from breast cancer, Clin. Can. Res., 2003, 9, 5435-5436). These patients have an extremely poor prognosis and intracerebral tumors are often the cause of death. Autopsy revealed that 20-30% of patients who die of breast cancer have brain metastases (Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD and Sampson. JH; Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer, CHn. Can. Res., 2003, 9, 5514-5520).
Human cytomegalovirus (CMV) is a widespread opportunistic human herpes virus that causes severe and fatal diseases in those who arc immune compromised and in transplant recipients. CMV is also a leading cause of atherosclerosis and virally mediated birth defects. The human CMV uses the EGFR receptor to enter cells during infection, EGFR is autophosphorylated and the downstream signal transduction pathway components are activated; however, the EGFR specific inhibitor tyrphostin AG 1478 has been shown to reduce the viral load in cells that were infected in the presence of the tyrphostin (Wang X, et al., Nature, 24 July 2003, VoI 424, 456-461). Accordingly, potent EGFR selective inhibitors may be useful in anti-CMV therapy.
The Src family of tyrosine-kinases includes the sub-family proteins c-Src, Lyn, Fyn, Lck, Syk, Hck, Yes, BIk, Fgr and Frk. While various members of the c-Src family are important for normal cellular proliferation, their overexpression and overactivation can promote development of cancer (Yeatman TJ, Nature, June 2004, Vol. 4). For example, the Lyn kinase has been shown to be upregulated in hormone resistant prostate cancer. Tumor xenografts of hormone resistant prostate cancer cells showed delayed growth upon treatment with peptides that specifically block Lyn kinase activity (Goldenberg-Furmanov, et al., Cancer Research, 1 Feb 2004, 64, 1058-1064). The Lyn and Hck Src sub-family tyrosine-kinases have both been implicated in chronic myeloid leukemia (CML). CML is caused by the BCR-AbI fusion protein resulting from the t(9;22) chromosomal translocation that juxtaposes the c-Abl nonreceptor tyrosine kinase gene on chromosome 9 with a breakpoint cluster region (bcr) gene on chromosome 22. The BCR-AbI fusion protein is a constitutively activated form of the AbI tyrosine kinase that drives uncontrolled growth leading to CML and many cases of adult acute lymphoblastic leukemia. Gleevec is an inhibitor of AbI that has been successfully used to treat CML. However, Gleevec does not help patients in blast crisis because they carry mutant forms of BCR-AbI that no longer bind Gleevec. Such Gleevec resistant CML cells are sensitive to a dual src/BCR-Abl inhibitor that binds and inhibits the mutant BCR-AbI and members of the src family (Shah, et al., Science, 16 July 2004, VoI 305, 399-401). CML cells can also become resistant to treatment with the tyrosine kinase AbI inhibitor Gleevec in other ways. For example, CML K562 cells that become resistant to Gleevec minimize reliance on the BCR-AbI translocation for growth and instead upregulate the Lyn and Hck kinases, as demonstrated by expressing antisense Lyn in these cells, which reduced their rate of proliferation (Donato, et al., Blood, 15 Jan 2003, 101(2)). c-Src and other Src family members arc also involved in cellular adhesion, invasion and motility of tumor cells. Thus, small molecule inhibitors of the Src kinase family could offer new therapeutic opportunities for both leukemias and solid tumors.
Aurora kinases (Aurora- A5 Aurora-B and Aurora-C) are highly conserved tyrosine kinases found in all organisms where they function to regulate microtubule dynamics during the M phase of the cell cycle and are essential for mitotic progression. Aurora-A kinase associates with the centrosome around the pericentriolar material, as well as the microtubules at the bipolar mitotic-spindle poles and the midbody microtubules and plays a role in spindle formation and organization of the centrosome. Aurora-B regulates chromosomal movement and cytokinesis and Aurora-C's biological function is not yet understood. The Aurora-A kinase is involved in centrosome separation, duplication and maturation as well as in bipolar spindle assembly and stability. Aurora-A is overexpressed in a number of different human cancers and tumor cell lines. Overexpression of Aurora is sufficient to induce growth, in soft agar and transforms cells making them tumorigenic. Inhibition of Aurora activity results in centrosome/chromosome segregation defects leading to monopolar spindles and polyploidy which induces cell apoptosis in a variety of cancer cell lines and has suppressed tumor growth in vivo.
Angiogenesis plays a role in various processes including development of the vasculature, wound healing and maintenance of the female reproductive system. Pathological angiogenesis is associated with disease states such as cancer, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis. Solid-tumor cancers, in particular, are dependent on angiogenesis for their growth. The vascular endothelial growth factors (VEGFs) are mediators of both normal and pathologic angiogenesis. VEGF transmits signals into cells through their cognate receptors, which belong to the receptor tyrosine kinase (RTK) family of transmembrane receptors. These receptors are tripartite, consisting of an extracellular ligand-binding domain, a transmembrane domain, which anchors the receptor in the membrane of the cell, and an intracellular tyrosine kinase domain. One subfamily of RTKs comprises the receptors Fltl/VEGF-Rl and
KDR/Flkl /VEGF-R2, which bind VEGFs. Binding of the VEGF ligand to the receptor results in stimulation of the receptor tyrosine kinase activity and transduction of biological signals into the cell. The KDR/Flkl/VEGF-R2 receptor mediates the biological activities of mitogenesis and proliferation of endothelial cells while the Fltl /VEGF-Rl receptor mediates functions such as endothelial cell adhesion.
Inhibition of KDR/Flkl /VEGF-R2 signalling has been shown to inhibit the process of angiogenesis. Inhibitors of this receptor are likely useful in controlling or limiting angiogenesis.
There is a need for potent small-molecule kinase inhibitors of one or more of the EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF kinase proteins and the like possessing anti-tumor cell proliferation activity, and as such are useful in treating or ameliorating a EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF kinase receptor mediated, angiogenesis-mediated or hyperproliferative disorder.
U.S. Patent Nos. 6,232,320 and 6,579,882 (divisional of U.S. 6,232,320) and U.S. Patent Application Publication No. 2003220365 (divisional of U.S. 6,579,882) describe cell adhesion- inhibiting compounds.
SUMMARY OF THE INVENTION The present invention is directed to a compound of Formula (I):
Figure imgf000008_0001
and forms thereof, wherein L, R1, R2 and R3 are as defined herein. An example of the present invention includes using a compound of formula (I) as a protein kinase inhibitor.
An example of the present invention includes a method for using a compound of formula (T) as an inhibitor of a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF comprising contacting the protein kinase domain or receptor with the compound.
An example of the present invention includes a method for using a compound of formula (I) and forms, pharmaceutical compositions or medicaments thereof in treating, preventing or ameliorating a kinase mediated disorder. The present invention is further direct to a method for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I) or a form thereof.
These and other aspects and advantages of the invention, which will become apparent in light of the detailed description below, are achieved through use of the compounds of this invention.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides thienopyrimidine compounds of Formula (I):
Figure imgf000009_0001
and a form thereof, wherein L is selected from the group consisting of NH and O;
Ri is selected from the group consisting of aryl-Ra, heteroaryl-Ra, heterocyclyl-Ra, d-salkyl-Ci-salkoxy, Ci-galkyl-aryl-Ra Ci-salkyl-heteroaryl-Ra and Ci -salkyl-heterocyclyl-Ra;
Ra is one, two, three or four substitucnts each selected from the group consisting of hydrogen, halogen, Ci-salkyl, Ci.salkyl-halo, Ci-galkyl-hydroxy, Ci-salkoxy,
Ci.8alkoxy-h.alo, Ci-salkoxy-hydroxy, amino, Ci-salkyl-amino, arnino-Cx-salkyl, Ci-8alkyl-amino-Ci-8alkyl, cyano, aryl-Rb, heteroaryl-Rb, heterocyclyl-Rb, Ci-salkyl-aryl-Rb, Ci-8alkyl-heteroaryl-Rb, C^salkyl-heterocyclyl-Rb, Ci-salkyl-amino-aryl-Rb, Ci-sahcyl-amino-hetero aryl-Rb, Ci-salkyl-amino-heterocyclyl-Rb, Ci_8alkyl-amino(Ci-8alkyl)-aryl-Rb,
Ci-salkyl-amino^i-salkyO-heteroaryl-Rb,
Ci-8alkyl-amino(Ci.8alkyl)-heterocyclyl-Rb, Ci-saUcyl-amino-Ci-salkyl-aryl-Rb, Ci-salkyl-amino-Ci-salkyl-heteroaryl-Rb, Ci-salkyl-amino-Ci-salkyl-heterocyclyl-Rb, Ci-galkyl-amino^i-salkyO-Ci-salkyl-aryl-Rb, C1-8alkyl-amino(Ci-8alkyl)-Ci_8alkyl-heteroaryl-Rb, Ci-saUcyl-ammoCd-salky^-d-salkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb, sulfonyl-aryl-Rb, sulfonyl-heteroaryl-Rb, sulfonyl-heterocyciyl-Rb, carbamoyl, carbamoyl-Ci-salkyl, sulfonyl-arnino, sulfonyl-amino-C i-salkyl, sulfonyl-amino-Ci-salkyl-amino and sulfonyl-amino-C i-salkyl-amino-C i-salkyl; Rb is one, two, three or four substituents each, selected from, the group consisting of
Ci-salkyl, Q-salkoxy, cyano, halo, hydroxy, amino and amino-Cj-galkyl; R2 is selected from the group consisting of aryl-Rc, heteroaryl-Rc and heterocyclyl-Rc; Rc is one, two, three or four substituents each selected from the group consisting of hydrogen, cyano, halogen, C^alkyl, Cμgalkyl-halo, C^salkyl-hydroxy, Ci-8allcoxy, Ci-salkoxy-halo, Ci-salkoxy-hydroxy, amino, Ci-salkyl-amino, amino-Ci-galkyl, Ci_8aLkyl-amino-Ci_8alkyl, oxyaryl, oxyheteroaryl and amidoaryl; and
R3 is selected from the group
Figure imgf000010_0001
and amino.
An example of the present invention is a compound of Formula (I) and a form thereof wherein L is NH.
An example of the present invention is a compound of Formula (I) and a form thereof wherein L is O.
An example of the present invention is a compound of Formula (I) and a form thereof wherein Ri is selected from the group consisting of aryl-Ra, hctcroaryl-Ra, Ci-salkyl-Ci-galkoxy, Ci-salkyl-aryl-Ra and Ci-salkyl-heterocyclyl-Ra.
An example of the present invention is a compound of Formula (I) and a form thereof wherein
Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-galkoxy, Cj-galkoxy-halo, C^alkyl-arnino-d-salkyl, heterocyclyl-Rb, Ci^aliyl-heterocyclyl-Rb, Ci-saUcyl-amino^i-salky^-heterocyclyl-Rb, Ci-8aUsyl-amino(Ci-8alkyl)-Ci-8alkyl-heterocyclyl-Rb, oxyaryl-Rb and sulfonyl-amino-C i-galkyl-amino-Ci-sallcyl; and
Rb is Ci_8alkyl.
An example of the present invention is a compound of Formula (I) and a form thereof wherein R2 is selected from the group consisting of aryl-Rc and heteroatyl-Rc; and
Rc is one or two substituents each selected from the group consisting of hydrogen, halogen, Ci-salkyl, oxyaryl and amidoaryl.
The present invention is further directed to a compound of Formula (Ia):
Figure imgf000011_0001
and a form thereof, wherein
R1 is selected from the group consisting of aryl-Ra, heteroaryl-Ra, Ci-galkyl-aryl-Ra and Ci-galkyl-heterocyclyl-Ra; Ra is one or two substituents each selected from the group consisting of hydrogen,
Ci-8alkoxy, Ci-salkoxy-halo,
Figure imgf000011_0002
heterocyclyl-Rb, Ci-salkyl-heterocycly 1-Rb, C1-8alkyl-amino(C1-8alkyl)-heterocyclyl-Rb,
Ci _8alkyl-amino(C i .galkyFj-C i .galkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb and sulfonyl-amino-Ci.salkyl-amino-Ci.galkyl; Rb is Ci-βalkyU
Rc is one or two substituents each selected from the group consisting of hydrogen, halogen, Ci.8alkyl, oxyaryl oxyheteroaryl and amidoaryl; and
R3 is selected from the group consisting
Figure imgf000011_0003
and amino.
An example of the present invention is a compound of Formula (Ia) and a form thereof wherein R1 is selected from the group consisting of phenyl-Ra, pyridinyl-Ra, Ci-salkyl-phenyl-Ra,
Figure imgf000011_0004
Ci-salkyl-piperidinyl-Ra and Ci-galkyl-pyrrolidinyl-Ra.
An example of the present invention is a compound of Formula (Ia) and a form thereof wherein
Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-salkoxy, Ci-galkoxy-halo, Ci-gaUcyl-amino-Ci-salkyl, morpholin-4-yl-Rb, piperazinyl-Rb, C1-8aikyl-morpholin-4-yl-Rb, Q-salkyl-piperidinyl-Rb,
Ci.salkyl-amino^Lsalky^-pyranyl-Rb,
Ci-salkyl-amino^i-salkyO-Ci-saUcyl-tetrahydro-furanyl-Rb, oxyphenyl-Rb and sulfonyl-amino-Ci-sallcyl-amino-Ci-salkyl; and Rb is Ci-salkyl.
The present invention is further directed to a compound of Formula (Ib):
Figure imgf000012_0001
and a form thereof, wherein
Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-βalkoxy, Ci-salkoxy-halo, Ci-salkyl-ammo-Ci-galkyl, heterocyclyl-Rb,
Ci-salkyl-heterocyclyl-Rb, Ci-8alkyl-arnino(Ci.3alkyl)-heterocyclyl-Rb, Ci-8alkyl-amino(Ci-8alkyl)-Ci-8alkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb and sulfonyl-amino-Ci.salkyl-arnino-Ci.salkyl; and Rb is C,.8aliyl. An example of the present invention is a compound of Formula (Ib) and a form thereof wherein
Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-8alkyl-amino-Ci-8alkyl, Ci_8alkyl-heterocyclyl-Rb, Ci_saIkyl-amino(Ci-8alkyl)-heterocyclyl-Rb, Ci-8alkyl-amino(Ci-8alkyl)-Ci-8alkyl-heterocyclyl-Rb, oxyaryl-Rb and sulfonyl-amino-C i-salkyl-amino-C i-salkyl; and Rb is Ci_8alkyl.
An example of the present invention is a compound of Formula (Ib) and a form thereof wherein Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-salkyl-amino-C i-salkyl, Q-salkyl-morpholin-4-yl-Rb, Ci.8alkyl-piperidinyl-Rb, Ci-8alkyl-amino(Ci-8alkyl)-pyranyl-Rb, Ci-salkyl-amino^i-salky^-Ci-saLkyl-tetrahydro-furanyl-Rb, oxyphenyl-Rb and sulfonyl-amino-Ci-galkyl-amino-Ci-salkyl; and Rb is Ci-βalkyl. The present invention is farther directed to a compound of Formula (Tc):
Figure imgf000013_0001
and a form thereof, wherein
Ri is selected from the group consisting of aryl-Ra, heteroaryl-Ra, Ci_8alkyl-Ci-8alkoxy,
Ci-8alkyl-aryl-Ra and Cj-salkyl-heterocyclyl-Ra; Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-8alkoxy, Ci_8alkoxy-halo, Ci-salkyl-amino-Ci-salkyl, heterocyclyl-Rb, Ci-salkyl-heterocyclyl-Rb, Ci.salkyl-amino(Ci-8alkyl)-heterocyclyl-Rb, Ci_8alkyl-amino(Ci_8alkyl)-C1-8alkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb and sulfonyl-amino-Ci.salkyl-arruno-Ci-salkyl; Rb is Ci-8alkyl; and
Rci and Rc2 is each one or two substituents each selected from the group consisting of hydrogen, halogen, Ci-salkyl, oxyaryl, oxyheteroaryl and amidoaryl. An example of the present invention is a compound of Formula (Ic) and a form thereof wherein Ri is selected from the group consisting of phcnyl-Ra, pyridinyl-Ra, Ci-8alkyl-Ci_8alkoxy, Ci-8alkyl-phenyl-Ra, Ci_8alkyl-morpholin-4-yl-Ra, Ci_8alkyl-piperidinyl-Ra and Ci-salkyl-pyrrolidinyl-Ra.
An example of the present invention is a compound of Formula (Ic) and a form thereof wherein
Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-βalkoxy, Ci-salkoxy-halo, Ci-salkyl-amino-Ci-salkyl, morpholin-4-yl-Rb, piperazinyl-Rb,
Figure imgf000013_0002
Ci-salkyl-piperidinyl-Rb, Ci-8aUkyl-amino(Ci-saU<yl)-pyranyl-Rb,
Ci_8aUcyl-arnino(Ci-8aUcyl)-Ci-8aUcyl-tetrahydro-furanyl-Rb, oxyphenyl-Rb and
Figure imgf000013_0003
and Rb is Ci-salkyl. An example of the present invention is a compound of Formula (Tc) and a form thereof ψherein Rc1 and Rc2 is each one or two substituents each selected from the group consisting of hydrogen, halogen, Q-salkyl, oxyphenyl and amidophenyl.
An example of the present invention is a compound of Formula (I) and a form thereof, wherein R1, L, R2 and R3 is selected from:
Cpd R1 L R2 R3
1 4-OCH3-phenyl NH 4-F-3-Cl-phenyl NH2
2 (4-CH2-morpho1in-4-yl)-phenyl NH 4-F-3-Cl-phenyl NH2
3 3,4-(OCH3)2-phenyl NH 4-F-3-Cl-phenyl NH2
4 (CH2)2-morpholin-4-yl NH 4_F_3_Cl-phenyl NH2
5 4-Sθ2-NH(CH2)3-N(CH3)2-ρhenyl NH 4-F-3-Cl-phenyl NH2
6 4-phenoxy-phenyl NH 4-F-3-Cl-phenyl NH2
7 4-OCF3-phenyl NH 4-F-3-Cl-phenyl NH2
8 4-OCH(CH3)2-phenyl NH 4-F-3-Cl-phenyl NH2
9 6-OCH3-ρyridin-3-yl NH 4-F-3-Cl-phenyl NH2
10 (4-morpholin-4-yl)-phenyl NH 4-F-3-Cl-phenyl NH2
11 CH2-3,4-(OCH3)2-phenyl NH 4-F-3-Cl-phenyl NH2
12 (CH2)2-3,4-(OCH3)2-phenyl NH 4-F-3-Cl-phenyl NH2
13 (4-CH2-piperidin- 1 -yl)-phenyl NH 4-F-3-Cl-phenyl NH2
14 [4-CH2-N(CH3)2]-phenyl NH 4-F-3-Cl-phenyl NH2
15 {4-(CH2)2-N[(CH3)(tetrahydro- NH 4-F-3-Cl-phenyl NH2 pyran-4-y I)] } -phenyl
16 (4-CH2-N[(CH3)(CH2-(2i?)- NH 4-F-3-Cl-phenyl NH2 tetrahydro-furan-2-yl)] } -phenyl
17 {4-CH2-N[(CH3χCH2-(2,S)- NH 4-F-3-Cl-phenyl NH2 tetrahy dro-furan-2-yl)] } -phenyl
18 [4-CH2-(4-CH3-ρiρerazin- 1 -yl)]- NH 4-F-3-Cl-phenyl NH2 phenyl
19 (CH2)2-morpholin-4-yl O 4-F-2-CH3-indol-5-yl CH3
20 (4-CH2-morpholin-4-yl)-phenyl O 4-F-2-CH3-indol-5-yl CH3
21 (CH2)2-piperidin- 1 -yl O 4-F-2-CH3-indol-5-yl CH3
22 (CH2)2-pyrrolidin-l-yl O 4-F-2-CH3-indol-5-yl CH3
23 (4-CH2-morpholin-4-yl)-phenyl NH 4-phenoxy-phenyl CH3
24 (CH2)2-morpholin-4-yl NH 4-phenoxy-ρhenyl CH3 Cpd Ri R2 R3
25 (CH2)2-morpholin-4-yl NH [4-NHC(O)-phcnyl]- CH3 phenyl
26 (CH2)3-morpholin-4-yl NH [4-NHC(O)-phenyl]- CH3 phenyl
27 (CEb)2OCH3 O 4-F-2-CH3-indol-5-yl CH3
Compounds representative of a compound of Formula (I) or a form thereof include compounds and forms thereof selected from:
Figure imgf000015_0001
Cpd 1 Cpd 2 Cpd 3
Figure imgf000015_0002
Cpd 4 Cpd 5 Cpd 6
Figure imgf000015_0003
Cpd 7 Cpd 8 Cpd 9
Figure imgf000016_0001
CpdlO Cpdll Cpdl2
Figure imgf000016_0002
Cpdl3 Cpdl4 Cpdl5
Figure imgf000016_0003
Cpdlό Cpdl7 Cpd 18
Figure imgf000017_0001
Cpd 19 Cpd 20 Cpd 21
Figure imgf000017_0002
Cpd 22 Cpd 23 Cpd 24
Figure imgf000017_0003
Cpd 25 Cpd 26 Cpd 27
Chemical Definitions & Nomenclature
Bond lines drawn into a ting system from a substituent variable indicate that the substiruent may be attached to any of the substitutable ring atoms. As used herein, the following terms are intended to have the following definitions. The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term. The scope of the per se definition of the term is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.
The term "Ci-salkyl" means a saturated aliphatic branched or straight-chain hydrocarbon radical or linking group having from 1 up to 8 carbon atoms in a linear or branched arrangement, wherein the radical is derived by the removal of one hydrogen atom from a carbon atom and the linking group is derived by the removal of one hydrogen atom from each of two carbon atoms in the chain. The term "Q-salkyl" also includes a "Ci-6alkyl" and "C^alkyl" radical or linking group having from 1 up to 6 carbon atoms and 1 up to 4 carbon atoms respectively, such as methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3- hexyl, 1-heptyl, 2-heptyl, 3-heptyl, 1-octyl, 2-octyl, 3-octyl and the like. Alkyl radicals or linking groups may be attached to a core molecule and farther substituted on any chain carbon atom when allowed by available valences.
The term "Ci_8alkoxy" means an alkyl radical or linking group having from 1 up to 8 carbon atoms in a linear or branched arrangement, wherein the radical or linking group is attached through an oxygen linking atom, as in the formula: -O-Ci-βalkyl. The term "Cj-galkoxy" also includes a "Ci-βalkoxy" and
Figure imgf000018_0001
radical or linking group having from 1 up to 6 carbon atoms and from 1 up to 4 carbon atoms respectively, such as methoxy, ethoxy, propoxy, butoxy and the like. Alkoxy radicals or linking groups may be attached to a core molecule and further substituted on any chain carbon atom when allowed by available valences.
The term "C3_i2cycloalkyl" means a saturated or partially unsaturated cyclic hydrocarbon ring system radical. The term "C3-i2cycloalkyl" also includes a Ca-scycloalkyl, Cs-iocycloalkyl, Cs-βcycloalkyl, Cs-scycloalkyl, Cs-^cycloalkyl, C9-i3cycloalkyl or benzofused-C3-;i2cycloalkyl ring system radical and the like, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, IH-indenyl, indanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalenyl, acenaphthenyl, adamantanyl and the like. C3_i2cycloalkyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences. The term "aryl" means an unsaturated aromatic hydrocarbon ring system radical. Aryl ring systems include phenyl, naphthalenyl, azulenyl, anthracenyl and the like. Examples of aryl in compounds representative of the present invention include phenyl or naphthalenyl. Aryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
The term "hetero", when used as a prefix for a ring system, refers to the replacement of at least one carbon atom member in the ring system with a heteroatom selected from N, O, S, S(O), or SO2. A hetero ring may have 1, 2, 3 or 4 carbon atom members replaced by a nitrogen atom. Alternatively, a ring may have 1 , 2 or 3 nitrogen atom members and 1 oxygen or sulfur atom member. Alternatively, a ring may have 1 oxygen or sulfur atom member. Alternatively, up to two adjacent ring members may be heteroatoms, wherein one heteroatom is nitrogen and the other heteroatom is selected from N, S or O.
The term "heterocyclyl" means a saturated or partially unsaturated "hetero" ring system radical. Heterocyclyl ring systems include azetidinyl, 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, 2-imidazolinyl (also referred to as 4,5- dihydro-lH-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, tetrazolyl, tetrazolidiny], piperidinyl, l,4-dioxanyl, morphoHnyl, 1 ,4-dithianyl, thiomorpholinyl, piperazinyl, azepanyl, hexahydro-l,4-diazepinyl, hexahydro-l,4-oxazepanyl, tetrahydro-furanyl, tetrahydro-thienyl, tetrahydro-pyranyl, tetrahydro-pyridazinyl and the like. The term "heterocyclyl" also includes a benzofused-heterocyclyl ring system radical and the like, such as indolinyl (also referred to as 2,3-dihydro-indolyl), benzo[l,3]dioxolyl, 2,3-dihydro-l,4-benzodioxinyl, 2,3-dihydro-benzofuranyl, 1,2- dihydro-phthalazinyl and the like. Heterocyclyl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences. The term "hctcroaryl" means an unsaturated aromatic "hetero" ring system radical. Heteroaryl ring systems include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and the like. Heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
The term "heteroaryl" also includes a benzofused-heteroaryl ring system radical and the like, such as indolizinyl, indolyl, azaindolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, azaindazolyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, benzoisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8- naphthyridinyl, pteridinyl and the like. Benzofused-heteroaryl radicals may be attached to a core molecule and further substituted on any atom when allowed by available valences.
The term "Ci-8alkoxy-halo" means a radical of the formula: -0-Ci.salkyl-(halo)i.i7, wherein one or more halogen atoms may be substituted on Ci-8alkyl when allowed by available valences. The term "Ci-salkoxy-halo" also includes a Ci_4alkoxy-halo radical of the formula: -O-Ci-4alkyl-(halo)1_9, such as rnonofluoromethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy and the like.
The term "Ci-8alkoxy-hydroxy" means a radical wherein -O-C^salkyl is substituted on an available carbon chain atom with one or more hydroxy radicals.
The term "Ci-salkyl-d-salkoxy" means a radical of the formula: -Ci_8alkyl-O-Ci_8alkyl.
The term "Ci_8alkyl-ammo" means a radical of the formula: -C1-SaIlCyI-NH2.
The term "Ci_8alkyl-amino-Ci_sallcyl" means a radical of the formula: -Ci-salkyl-NH-Ci-galkyl or -Ci-8alkyl-N(Ci-8alkyl)2.
The term "Ci-salkyl-amino-aryl" means a radical of the formula: -Ci-salkyl-NH-aryl.
The term
Figure imgf000020_0001
means a radical of the formula: -Ci-galkyl-NH-heteroaryl.
The term "Ci-salkyl-amino-heterocyclyl" means a radical of the formula: -Ci-salkyl-NH-heterocyclyl. The term "Ci-saU-yl-amino(Ci_8alkyl)-aryl" means a radical of the formula:
-Ci_8alkyl-N(Ci-8alkyl)-aryl.
The term "C1-8alkyl-amino(Ci-8ahcyl)-heteroaryl" means a radical of the formula: -Ci-salkyl-NCd-salky^-heteroaryl.
The term "C1-8alkyl-amino(Ci-8alkyl)-heterocyclyl" means a radical of the formula: -Ci_8alkyl-N(Ci-8alkyl)-heterocyclyl.
The term "d-salkyl-amino-Ci-salkyl-aryl" means a radical of the formula: -Ci-salkyl-NH-Ci-galkyl-aryl.
The term "Ci-salkyl-amino-Ci-salkyl-heteroaryl" means a radical of the formula: -Ci-galkyl-NH-Ci-galkyl-heteroatyl.
The term "Ci.galkyl-amino-Ci.galkyl-heterocyclyl" means a radical of the formula: -Cusalkyl-NH-Ci-salkyl-heterocyclyl.
The term "Ci-salkyl-amino(Ci.8alkyl)-Ci-salkyl-aryl" means a radical of the formula: -C i-8alkyl-]N (Chalky Q-CVsalkyl-aryl.
The term "Ci-galkyl-amino^i-galkyty-Ci-salkyl-heteroaryl" means a radical of the formula: -Ci-8alkyl-N(C1.8alkyl)-C1_8alkyl-heteroaryl.
The term "Ci-8alkyl-arnino(Ci.8alkyl)-Ci-8aLkyl-heterocyclyl" means a radical of the formula: -Ci-8alkyl-N(Ci_8alkyl)-C1-salkyl-hctcrocyclyl. The term "Ci.8alkyl-aryl" means a radical of the formula: -Ci-salkyl-aryl.
The term "Ci-galkyl-halo" means a radical of the formula: -C1-SaUCyI-(IIaIo)1-I7., wherein one or more halogen atoms may be substituted on C^alkyl when allowed by available valences. The term "Ci-salkyl-halo" also includes a radical of the formula: -Ci-4alkyl-(halo)i-9, such as monofluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl and the like.
The term "Ci_galkyl-heteroaryl" means a radical of the formula: -Ci-saLkyl-heteroaryl.
The term "Ci-galkyl-heterocyclyl" means a radical of the formula: -Ci-salkyl-heterocyclyl. The term "Ci-galkyl-hydroxy" means a radical wherein Cj-salkyl is substituted on an available carbon chain atom with one or more hydroxy radicals.
The term "amidoaryl" means a radical of the formula: -NHC(O)-aryl.
The term "amino" means a radical of the formula: — ' NH2.
The term "amino-Ci-8alkyl" means a radical of the formula: -KfH-Ci-salkyl or -N(C1-8alkyl)2.
The term "carbamoyl" means a radical of the formula: -C(O)NH2.
The term "carbamoyl-d-gallcyl" means a radical of the formula: -C(O)NH-Ci.8alkyl or -C(O)N(Ci-8alkyl)2.
The term "halogen" or "halo" means the group chloro, bromo, fluoro or iodo. The term "oxyaryl" means a radical of the formula: -O-aryl.
The term "oxyheteroaryl" means a radical of the formula: -O-heteroaryl.
The term "sulfonyl-amino" means a radical of the formula:
Figure imgf000021_0002
The term "sulfonyl-amino-Ci.salkyl" means a radical of the formula: -SO2-NH-Ci-8a]kyl or -SO2-N(Ci_8alkyl)2 and the like.
The term "sulfonyl-amino-Q-salkyl-amino" means a radical of the formula: -SOz-NH-Ci-salkyl-NEb, -SO2-N(Ci-8alkyl)-Ci^alkyl-NH2 or -SO2-N(C i-8alkyl-NH2)2 and the like. The term "sulfonyl-aπύno-C1_8alJkyl-aimno-Ci-8alkyl" means a radical of the formula: -SO2-NH-Ci.8alk^l-NH-Ci-8alJcyl, -SO2-N(C4-8alkyl)-Ci-8alkyl-NH-C1-8alkyl, -SO2-N(Ci_8alkyl)-Ci.8a]%l-N(Ci.8alkyl)2, -SO2-N(Ci.8alkyl-NH-C1-8alkyl)2 or -SO2-N[C,-8alkyl-N(C,-8alkyl)2]2 and the like.
The term "sulfonyl-aryl" means a radical of the formula: -Sθ2-aryl. The term "sulfonyl-heteroaryl" means a radical of the formula: -S02-heteroaryl.
The term "sulfonyl-heterocyclyl" means a radical of the formula: -SO2-heterocyclyl.
The term "substituted" means the independent replacement of one or more hydrogen atoms within a radical with that amount of substirutents allowed by available valences.
The term "dependency selected" means that the structure variables are specified in an indicated combination.
Tn general, TUPAC nomenclature rules are used herein.
Compound Forms
The term "form" means, in reference to compounds of the present invention, such may exist as, without limitation, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof. The term "isolated form" means, in reference to compounds of the present invention, such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or ti'ans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such compound forms and mixtures thereof. The compounds of the invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the "pharmaceutically acceptable salts" of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms. Suitable salt forms include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of an acid such as acetic acid, adipic acid, benzoic acid, carbonic acid, citric acid, fumaric acid, glycolic acid, hydrochloric acid, maleic acid, malonic acid, phosphoric acid, saccharinic acid, succinic acid, sulphuric acid, tartaric acid, trifluoro acetic acid and the like.
Furthermore when the compounds of the present invention carry an acidic moiety, suitable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligatids, e.g. quaternary ammonium salts.
Thus, representative salts include the following: acetate, adipate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulphonate), carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, fumarate, gluconate, glutamate, glyconate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, malonate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, saccharinate, salicylate, stearate, sulfate, succinate, tartrate, tosylate, trichloroacetate, trifluoroacetate and the like.
Examples of salt forms of compounds representative of the present invention include the monohydrochlori.de salt.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry. ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis. 3rd Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. The scope of the present invention encompasses all such protected compound forms and mixtures thereof. The invention includes compounds of various isomers and mixtures thereof.
The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (optical isomers).
The term "optical isomer" means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of 5 polarized light in different directions. The term "optical activity" means the degree to which an optical isomer rotates the plane of polarized light.
The term "racemate" or "racemic mixture" means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity. 0 The term "enantiomer" means an isomer having a nonsuperimposable mirror image. The term "diastereomer" means stereoisomers that are not enantiomers.
The term "chiral" means a molecule which, in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules which can be superimposed on their mirror images.
15 The two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right handed), abbreviated D, depending on which way they rotate polarized light. The symbols "R" and "S" represent the configuration of groups around a stereogenic carbon atom(s).
An example of an isolated form of an achiral mixture includes a dextrorotatory 0 enantiomer, wherein the mixture is substantially free of the levorotatory isomer. In this context, substantially free means the levorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10 %, less than 5 %, less than 2 % or less than 1 % of the mixture according to the formula:
. . . (mass levorotatoiγ) n /ΛΛ
% levorotatory = - — x 100
(mass dextrorotatory) + (mass levorotatory)
25 Similarly, an example of an isolated form of an achiral mixture includes a levorotatory enantiomer, wherein the mixture is substantially free of the dextrorotatory isomer. In this context, substantially free means the dextrorotatory isomer may, in a range, comprise less than 25% of the mixture, less than 10 %, less than 5 %, less than 2 % or less than 1 % of the mixture according to the formula: α (mass dextrorotatory) 1 Λn
30 % dextrorotatoiy — — x 100
(mass dextrorotatory) + {mass levorotatory)
The term "geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration. In the "E" configuration, the substituents are on opposite sides in relationship to the carbon- carbon double bond. In the "Z" configuration, the substituents are oriented on the same side in relationship to the carbon-carbon double bond.
Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the "cis" configuration, the substituents are on the same side in relationship to the plane of the ring; in the "trans" configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of "cis" and "CTaUS" species are designated "cis/trans".
The isomeric descriptors ("R," "S," "E," and "Z") indicate atom configurations and are intended to be used as defined in the literature.
The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include combining the free base (or free acid) of each isomer of an isomeric pair using an optically active acid (or base) to form an optically active salt (followed by fractional crystallization and regeneration of the free base), forming an ester or amide of each of the isomers of an isomeric pair by reaction with an appropriate chiral auxiliary (followed by fractional crystallization or chromatographic separation and removal of the chiral auxiliary), or separating an isomeric mixture of either an intermediate or a final product using various well known chromatographic methods.
Furthermore, compounds of the present invention may have one or more polymorph or amorphous crystalline forms and, as such, are intended to be included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like) and, as such, are also intended to be encompassed within the scope of this invention..
Methods of Use
The compounds of formula (I) are inhibitors of a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF, having an IC5O (50% inhibition concentration) or an EC50 (50% effective concentration) in a range of about 50 μM or less, of about 25 μM or less, of about 15 μM or less, of about 10 μM or less, of about 5 μM or less, of about 1 μM or less, of about 0.5 μM or less, of about 0.25 μM or less or of about 0.1 μM or less. The present invention includes a compound of formula (I) and forms thereof as a protein kinase inhibitor, wherein the protein kinase is selected from EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF.
The present invention includes a prodrug form of a compound of formula (T) and forms thereof as a protein kinase inhibitor. The present invention includes a metabolite form of a compound of formula (I) and forms thereof as a protein kinase inhibitor.
The present invention includes an isolated form of a compound of formula (1) and forms thereof as a protein kinase inhibitor.
The present invention includes a compound of formula (I) or a form thereof, wherein the compound is labeled with a ligand for use as a marker, and wherein the ligand is a radioligand selected from deuterium, tritium and the like.
The present invention includes use of a compound of formula (I) and forms thereof as an inhibitor of a protein kinase such as EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF comprising contacting the protein kinase domain or receptor with the compound.
The present invention includes the use of a compound of formula (I) and forms thereof as a pharmaceutical composition, medicine or medicament for treating, preventing or ameliorating a kinase mediated disease, disorder or condition.
The present invention includes the use of a compound of formula (I) and forms thereof as a medicament.
The present invention includes the use of a compound of formula (I) and forms thereof in the manufacture of a medicament for treating, preventing or ameliorating a kinase mediated disease, disorder or condition.
The present invention includes the use of a prodrug of a compound of formula (I) and forms thereof as a pharmaceutical composition, medicine or medicament for treating, preventing or ameliorating a kinase mediated disease, disorder or condition.
The present invention includes the use of a prodrug of a compound of formula (I) and forms thereof as a medicament. The present invention is directed to a method for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I) and forms thereof. The method of the present invention further comprises administering to the subject an effective amount of a prodrug of a compound of formula (I) and forms thereof.
The method of the present invention further comprises treating, preventing or ameliorating a chronic or acute EGFR, HER-2, c-Src, Lyn, c-Abl, Aurora-A or VEGF mediated disease, disorder or condition.
The method of the present invention wherein the disease, disorder or condition is associated with increased or unregulated protein kinase activity, expression or signaling and the like in the subject.
The method of the present invention further comprises administering to the subject an effective amount of a compound of formula (I) as a pharmaceutical composition, medicine or medicament thereof.
The method of the present invention wherein the disease, disorder or condition is an EGFR kinase mediated head or brain cancer in the subject, and wherein the compound penetrates the blood brain barrier. The method of the present invention further comprises treating or ameliorating nerve damage and promoting axon regeneration subsequent to a brain or spinal cord injury in the subject, wherein the compound is an EGFR inhibitor.
The method of the present invention further comprises treating, preventing or ameliorating viral infection by an EGFR kinase mediated cytomegalovirus in the subject.
The term "chronic or acute protein kinase mediated disease, disorder or condition" as used herein, includes, and is not limited to diseases, disorders or conditions associated with unregulated kinase activity and conditions that accompany such activity. The term "unregulated protein kinase activity, expression or signaling" refers to
1) increased or unregulated kinase expression or signaling, 2) increased kinase expression leading to unregulated cell proliferation, 3) increased kinase signalling leading to unregulated cell proliferation, or 4) mutations leading to constitutive kinase activation. The existence of unregulated kinase activity may be determined by procedures well known in the art.
The term "unregulated cell proliferation" refers to cell proliferation of one or more subset of cells in a multicellular organism resulting in harm (such as discomfort or decreased life expectancy) to the multicellular organism.
Tumor cells which result from unregulated cell proliferation use many mechanisms to enhance their survival and spread and often have high rates of proliferation because growth control signals that keep normal cells in check are defective. Many tumor cells secrete autocrine growth factors that increase proliferation rates or they induce other cells to secrete growth factors that they utilize.
Tumor cells grow and spread by dislodging from a primary tumor site, using proteases to digest the extracellular matrix, spreading in response to migration cues, allowing them to migrate to certain tissues preferentially where overexpressed adhesion molecules allow attachment and growth at the new site. The totality of these and other biological processes are responsible for the lethal effects of a tumor. A kinase inhibitor may affect one or more aspects of tumor survival mechanisms and thus be therapeutically useful. Alternatively, a kinase inhibitor may not affect one particular tumor survival mechanism but may still be therapeutically useful by affecting tumor survival by an unknown or as yet unelucidated mechanism of action. The foregoing methods contemplate that a compound of formula (I) or a form thereof is useful for treating, preventing or ameliorating diseases, disorders or conditions such as, without limitation, osteoarthritis, rheumatoid arthritis, synovial pannus invasion in arthritis, multiple sclerosis, myasthenia gravis, diabetes mellitus, diabetic angiopathy, diabetic retinopathy, retinal vessel proliferation, inflammatory bowel disease, Crohns disease, ulcerative colitis, bone diseases, transplant or bone marrow transplant rejection, lupus, chronic pancreatitis, cachexia, septic shock, fibroproliferative and differentiative skin diseases or disorders, central nervous system diseases, neurodegenerative diseases, disorders or conditions related to nerve damage and axon degeneration subsequent to a brain or spinal cord injury, acute or chronic cancer, occular diseases, viral infections, heart disease, lung or pulmonary diseases or kidney or renal diseases.
Certain diseases, disorders or conditions further include, without limitation, acute or chronic cancer selected from bladder cancer, brain, head or neck cancer, breast cancer, colorectal cancer, endometrial cancer, epidermoid cancer, esophageal cancer, gastric cancer, glioma cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, Kaposi's sarcoma, leukemia, lymphoma or papillocarcinoma; and, cancer-associated pathologies selected from abnormal cell proliferation, unregulated cell proliferation, tumor growth, tumor angiopathy, tumor angiogenesis, tumor vascularization or metastatic cancer cell invasion and migration.
Certain diseases, disorders or conditions further include, without limitation, fibroproliferative and differentiative skin diseases or disorders selected from papilloma formation, psoriasis, dermatitis, eczema, seborrhea or chcmothcrapy-induccd alopecia; central nervous system diseases selected from Alzheimer's disease, Parkinson's disease or depression; occular diseases selected from macular degeneration, diseases of the cornea or glaucoma; viral infections selected from mycotic infection, autoimmune disease or cytomegalovirus; heart disease selected from atherosclerosis, neointima formation or transplantation-induced vasculopathies such as arterial restenosis; lung or pulmonary diseases selected from allergic-asthma, lung fibrosis, pulmonary fibrosis or chronic obstructive pulmonary disorder; and, kidney or renal diseases selected from acute, subacute or chronic forms of glomerulonephritis or membranoproliferative glomerulonephritis, glomerulosclerosis, congenital multicystic renal dysplasia or kidney fibrosis. Certain HERl kinase mediated cancer includes, without limitation, bladder cancer, brain, head or neck cancer, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioma cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer or renal cell cancer.
Certain HER2 kinase mediated cancer includes, without limitation, bladder cancer, brain, head or neck cancer, breast cancer, colorectal cancer, gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, prostate cancer or renal cell cancer.
The term "administering," with respect to the methods of the present invention, refers to a means for treating, ameliorating or preventing a disease, disorder or syndrome as described herein with a compound of formula (I) or a form thereof, which would obviously be included within the scope of the invention albeit not specifically disclosed for certain of said compounds.
Such methods include therapeutically or prophylactically administering an effective amount of compound of formula (T) or a form thereof at different times during the course of a therapy or concurrently in a combination form. Such methods further include administering an effective amount of said compound with one or more agents at different times during the course of a therapy or concurrently in a combination form. The term "prodrug" means a compound of formula (1) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions. Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. The term "metabolite" means a prodrug form of a compound of formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a relatively less active functional derivative of said compound.
The term "subject" as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a disease or disorder or having a disease or disorder related to unregulated kinase activity.
The term "effective amount" refers to that amount of a compound of formula (I) or a form, pharmaceutical composition, medicine or medicament thereof that elicits the biological or medicinal response (such as inhibiting activation of unregulated kinase activity) in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
The effective amount of said compound is from about 0.001 mg/kg/day to about 300 mg/kg/day. In another embodiment the effective amount of said compound is from about 0.01 mg/kg/day to about 30 mg/kg/day.
The term "pharmaceutical composition" refers to a product containing a compound of formula (I) or a form thereof, such as a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from such combinations of the specified ingredients in the specified amounts.
The term "medicament" or "medicine" refers to a product containing a compound of formula (I) or a form thereof. The present invention includes use of such a medicament for treating, preventing or ameliorating a chronic or acute kinase mediated disease, disorder or condition.
The term "pharmaceutically acceptable" refers to molecular entities and compositions that are of sufficient purity and quality for use in the formulation of a pharmaceutical composition, medicine or medicament of the present invention and that, when appropriately administered to an animal or a human, do not produce an adverse, allergic or other untoward reaction. Since both human use (clinical and over-the- counter) and veterinary use are equally included within the scope of the present invention, a pharmaceutically acceptable formulation would include a pharmaceutical composition, medicine or medicament for either human or veterinary use. The term "combination form" refers to the use of a combination product comprising a compound of formula (I) or a form, pharmaceutical composition, medicine or medicament thereof and at least one therapeutic agent for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition. Advantageously, the effective amount of a combination product for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition may be a reduced amount of either or both the compound or therapeutic agent compared to the effective amount of the compound or therapeutic agent otherwise recommended for treating, preventing or ameliorating the disease, disorder or condition. Therefore, it is contemplated that the compound is administered to the subject before, during or after the time the agent is administered.
The term "therapeutic agent" refers to chemotherapeutic agents used to treat a kinase mediated cancer or antiviral agents used to treat cytomegalovirus. Chemotherapeutic agents include and are not limited to anti-angiogenic agents, anti- tumor agents, cytotoxic agents, inhibitors of cell proliferation, radiation therapy and the like or a combination thereof.
The term "treating, preventing or ameliorating" refers, without limitation, to facilitating the eradication of, inhibiting the progression of or promoting stasis of a chronic or acute kinase mediated disease, disorder or condition.
The term "radiation therapy" refers to a therapy that comprises exposing the subject in need thereof to radiation. The present invention includes a method for administering a compound of formula (I) or a form, pharmaceutical composition, medicine or medicament thereof in combination with radiation therapy. Procedures for administering such therapy are known to those skilled in the art. The appropriate scheme of radiation therapy will be similar to those already employed in clinical therapies wherein the radiation therapy is used alone or in combination with other chcmothcrapcutic agents. The present invention includes a pharmaceutical composition comprising an admixture of a compound of formula (I) or a form thereof and one or more pharmaceutically acceptable excipients.
The present invention includes a process for making a pharmaceutical composition, medicine or medicament comprising mixing a compound of formula (I) or a form thereof and an optional pharmaceutically acceptable carrier. The present invention includes a pharmaceutical composition, medicine or medicament resulting from the process of mixing a compound of formula (I) or a form thereof and an optional pharmaceutically acceptable carrier. Contemplated processes include both conventional and unconventional pharmaceutical techniques. Said pharmaceutical composition, medicine or medicament may take a wide variety of forms to effectuate mode of administration, wherein the mode includes, and is not limited to, intravenous (both bolus and infusion), oral, nasal, transdermal, topical with or without occlusion, and via injection intraperitoneally, subcutaneously, intramuscularly, intratumorally, intracerebrally or intracranially. The composition, medicine or medicament may be in a dosage unit such as a tablet, pill, capsule, powder, granule, sterile parenteral solution or suspension, mctcrcd aerosol or liquid spray, drop, ampoule, auto-injector device or suppository for such administration modes.
Pharmaceutical compositions, medicines or medicaments suitable for oral administration include solid forms such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules and powders; and, liquid forms such as solutions, syrups, elixirs, emulsions and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions. Alternatively, the pharmaceutical composition, medicine or medicament may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. The dosage form (tablet, capsule, powder, injection, suppository, teaspoonful and the like) containing the pharmaceutical composition, medicine or medicament contains an effective amount of the active ingredient necessary to be therapeutically or prophylactically effective as described above. The pharmaceutical composition, medicine or medicament may contain, from about 0.001 mg to about 5000 mg (preferably, from about 0.001 to about 500 mg) of a compound of formula (I) or a form thereof and may be constituted into any form suitable for the mode of administration selected for a subject in need.
An example of a contemplated effective amount for a pharmaceutical composition, medicine or medicament of the present invention may range from about 0.001 mg to about 300 mg/kg of body weight per day. In another example, the range is from about 0.01 mg/kg to about 30 mg/kg of body weight per day. In another example, the range is from about 0.003 to about 100 mg/kg of body weight per day. In another example, the range is from about 0.005 to about 15 mg/kg of body weight per day. The pharmaceutical composition, medicine or medicament may be administered according to a dosage regimen of from about 1 to about 5 times per day.
For oral administration, the pharmaceutical composition, medicine or medicament is preferably in the form of a tablet containing, e.g., 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of a compound of formula (ϊ) or a form thereof for the symptomatic adjustment of the dosage to the patient to be treated. Optimal dosages will vary depending on factors associated with the particular patient being treated (e.g., age, weight, diet and time of administration), the severity of the condition being treated, the particular compound being used, the mode of administration and the strength of the preparation. The use of either daily administration or post-periodic dosing may be employed. A representative compound, of formula (T) or a form thereof includes a compound selected from:
Cpd Name
1 5-arjdno-4-(3-chloro-4-fluoro-phenylamino)-thieno[23-d]pyritnidine-6- carboxylic acid (4-methoxy-phenyl)-amide,
2 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-morpholin-4-ylmethyl-phenyl)-amide,
3 5-armno-4-(3-chloro-4-flυoro-phenylainino)-tliieno[2,3-d]pyrirnidme-6- carboxylic acid (3,4-dimethoxy-phenyl)-amide,
4 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (2-morpholin-4-yl-ethyl)-amide,
5 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-(3-dimethylaim'no-propylsulfamoyl)-phenyl]-amide,
6 5-amino-4-(3-cbloro-4-fIuoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-phenoxy-phenyl)-amide,
7 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-trifluoromethoxy-phenyl)-amide,
8 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-isopropoxy-phenyl)-amide,
9 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyriτm'dine-6- carboxylic acid (6-methoxy-pyridin-3-yl)-amide,
10 5-arrάno-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrirrιidirie-6- carboxylic acid (4-m.orpholin-4-yl-phenyl)-amide,
1 1 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid 3,4-dimethoxy-benzylarnide,
12 5-arnino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]ρyrirnidine-6- carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl] -amide,
13 5-amino-4-(3-chloro-4-fluoro-pb.enylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-piρeridin-l-ylmethyl-phenyl)-amide, Cpd Name
14 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyriinidine-6- carboxylic acid (4-dimcthylaminomcthyl-phcnyl)-amidc,
15 5 -amino-4-(3 -chloro-4-fluoro-pheny lamino)-thieno [2,3 -d]pyrimidine-6- carboxylic acid (4- {2-[methyl-(tetrahydro-pyran-4-yl)-amino]-ethyl} - phenyl)-aτnide,
16 5-aiΗino-4-(3-chloro-4-fluoro-phcnylamino)-thicno[2,3-d]pyrimidinc-6- carboxylic acid [4-({methyl-[(2i?)-tetrahydro-furan-2-ylmethyl]-amino} - methyl)-phenyl] -amide,
17 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-( {methyl-[(2iS)-tetrahydro-furan-2-ylmethyl]-amino} - methyl)-phenyl]-amide,
18 5-ainino-4-(3-cliloro-4-fluoro-pheαylainino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-(4-methyl-piperazin- 1 -ylmethyl)-phenyl]-amide,
19 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thien.o[2,3- d]pyrimidine-6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide,
20 4-(4-£luoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (4-morpholin-4-ylmethyl-phenyl)-amide,
21 4-(4-fluoro-2-metliyl-lH-mdol-5-yloxy)-5-metliyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-piperidin-l-yl-ethyl)-amide,
22 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-pyrrolidin-l-yl-ethyl)-amide,
23 5-metb.yl-4-(4-phenoxy-plienylamino)-thieno[2,3-d]pyπmidine-6- carboxylic acid (4-morpholin-4-ylmethyl-phenyl)-amide,
24 4-(4-benzoylamino-phenylamino)-5-methyl-tliieno[2,3-d]pyrimidine-6- carboxylic acid (2-morpholin-4-yl-ethyl)-amide,
25 4-(4-benzoylamino-phenylam.ino)-5-methyl-thieno[2,3-d]pyrimidine-6- carboxylic acid (2-morpholin-4-yl-ethyl)-amide, Cpd Name
26 4-(4-benzoylainino-phenLylamino)-5-rnethyl-thieno[2,3-d.]pyrimidine-6- carboxylic acid (3-morpholin-4-yl-propyl)-amidc, or
27 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-methoxy-eth.yl)-arnide.
A representative compound of formula (I) or a form thereof includes a compound selected from:
Cpd Name
2 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-morpholin-4-ylmethyl-phenyl)-amide,
5 5-amino-4-(3-chloro-4-fluoro-phenylarxiino)-thieno[2,3-d]pyrimidine-6-- carboxylic acid [4-(3-dimethylamino-propylsulfamoyl)-phenyl]-amide,
13 5-amino-4-(3-chloro-4-fluoro-phenylarjiino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-piperidin-l-ylmethyl-phenyl)-arnide,
14 5-arjdno-4-(3-chloro-4-fluoro-phenylarnino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-dimethylaminomethyl-phenyl)-amide,
15 5-amino-4-(3-chloro-4-fluoro-phenylamino)-tliieno[2,3-d]pyrimidine-6- carboxylic acid (4-{2-[methyl-(tetrahydro-pyran-4-yl)-amino]-ethyl}- phcnyl)-amidc,
16 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-( {mcthyl-[(2i?)-tctrahydro-furan-2-ylmcthyl]-amino} - methyl)-phenyl]-amide5
17 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-({inethyl-[(2)S)-tetraliydro-furan-2-ylm.ethyl]-amino}- methyl)-phenyl] -amide,
18 5-arnino-4-(3-chloro-4-fluoro-phenylam.ino)-thieno[2,3-d.]pyrirnidine-6- carboxylic acid [4-(4-methyl-piperazin-l-ylmethyl)-phenyl]-arnide, or Cpd Name
27 4-(4-fluoro-2-mcthyl-lH-indol-5-yloxy)-5-mcthyl-thicno[23- d]pyrimidine-6-carboxylic acid (2-methoxy-ethyl)-amide.
A representative form of a compound of formula (I) includes a compound selected from:
Cpd Name
2 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[23-d]pyrimidine--6- carboxylic acid (4-morpholm-4-ylmethyl~ρhenyl)-amide TFA salt,
5 5-ammo-4-(3-chloro-4-fluoro-phenylarnino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-(3-dimethylamino-propylsulfamoyl)-phenyl]-amide TFA salt,
13 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrirnidine-6- carboxylic acid (4-piperidin-l-ylmethyl-phenyl)-amide TFA salt,
14 5-amino-4-(3-chloro-4-fluoro-phcnylanαino)-tMcno[2,3-d]pyrimidinc-6- carboxylic acid (4-dimethylaminomethyl-phenyl)-amide TFA salt,
15 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4- {2-[methyl-(tetrahydro-pyran-4-yl)-amino]-etb.yl} - phenyl)-amide TFA salt,
16 5-amino-4-(3-cb.loro-4-fluoro-prienylaπiino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-( {methyl-[(2i?)-tetrah.ydro-furan-2-ylmeth.yl]-amino} - methyi)-phenyl] -amide TFA salt,
17 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-({methyl-[(2»S)-tetraliydro-furan-2-ylmethyl]-arnino} - mcthyl)-phcnyl] -amide TFA salt,
18 5 -amino-4-(3 -chloro-4-fluoro-phenylamino)-thieno [2,3 -d]pyrimidine-6- carboxylic acid [4-(4-methyl-piperazin-l-ylmeth.yl)-phenyl]-amide TFA salt, or
27 4-(4-fluoro-2-methyl- 1 H-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-methoxy-ethyl)-amide TFA salt. Synthetic Methods
Representative compounds of the present invention can be synthesized in accordance with the general synthetic schemes described below and are illustrated more particularly in the specific synthetic examples that follow. The general schemes and specific examples are offered by way of illustration; the invention should not be construed as being limited by the chemical reactions and conditions expressed. The methods for preparing the various starting materials used in the schemes and examples are well within the skill of persons versed in the art. No attempt has been made to optimize the yields obtained in any of the example reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.
The terms used in describing the invention are commonly used and known to those skilled in the art. When used herein, the following abbreviations or formulas have the indicated meanings:
Abbreviation Meaning
CH3CN acetonitrile
Cpd compound
DIPEA diisopropylethylamine
DMF N,N-dimethyl formamide
EtOAc ethyl acetate
HATU O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate
KOtBu potassium t-butoxide min(s)/hr(s) minute(s)/hour(s)
NH2OH hydroxylamine
POCl3 phosphorus oxychioride
RT/rt/r.t. room temperature
SOCl2 thionyl chloride
TEA or Et3N triethylamine Abbreviation Meaning
TFA trifluoroacetic acid THF tetrahydrofuran
Scheme A
Figure imgf000039_0001
Pyrimidin.e-4,6-diol Compound Al is refluxed in. a reagent solution (such as POCI3 and the like in a solvent such as DMF and the like) to provide a 4,6-dichloro- pyrimidine-5-carbaldehyde Compound A2.
Figure imgf000039_0002
A solution of Compound A2 (in an acidic solvent such as acetic acid) is reacted with a reagent solution (such as hydroxylamine hydrochloride and the like in a solvent such as 10% aqueous ethanol and the like) to provide a 4,6-dichloro-pyrimidme-5- carbonitrile Compound A3.
Figure imgf000039_0003
Compound A3 is refhixed in the presence of a reagent solution (such as thionyl chloride and the like, with or without a co-solvent such as toluene, 1,2-dichloroethane and the like) to provide a 4,6-dichloro-pyrimidine-5-carbonitrile Compound A4 (as described in Kloetzer,W. and Herberz,M., Reactions of 4,6-dichloro-5- formylpyrimidine, Monatsheftefuer Chemie, 1965, 96(5), 1573-8).
Figure imgf000040_0001
A solution of Compound A5 (in a solvent such as THF, CH3CN, DMF, dioxane and the like; wherein L is as defined herein) is reacted with a solution of Compound A4 (in a solvent such as THF, CH3CN, DMF, dioxane and the like) in the presence of a base (such as DIPEA, Et3N and the like) to provide a Compound A6 (see also, ClarkJ. ct al.; J. Chem. Soc. Perkin Trans., 1976, 1, 1004-1007).
Figure imgf000040_0002
A solution of Compound A7 (in an organic base such as pyridine and the like, or in an organic base, such as TEA and the like containing a co-solvent such as THF, toluene and the like; wherein Rx is hydrogen or Ci-salkyl) is reacted with a solution of Compound A6 (in a solvent such as THF and the like) to provide a Compound A8.
Figure imgf000040_0003
A solution of Compound A8 (in a solvent such as THF and the like) is reacted with a solution of a base (such as IM potassium t-butoxide, triethylamine and the like in a solvent such as THF and the like) to provide a Compound A3 (For methyl ester derivatives of compounds like Compound A9 see, Clark, J. and Hitiris, G., Heterocyclic studies. Part 43. Thieno[2,3-d:4,5-d']dipyrimidines, Journal of the Chemical Society, Perkin Transactions 1 : Organic and Bio-Organic Chemistry (1972-1999) (1984), (9), 2005-8).
Figure imgf000041_0001
Compound A9 is reacted with a solution of Compound AlO (in a solvent such, as THF and the like) to provide a Compound All, representative of a compound of formula (I).
Scheme B
Figure imgf000041_0002
A solution of a commercially available Compound Bl (in a solvent such as DMF, dioxane and the like; wherein Rx is methyl) is reacted with a solution of a Compound A5 (in a solvent such as DMF, dioxane and the like) in the presence of a base (such as cesium carbonate and the like) to provide a Compound B2.
Figure imgf000041_0003
A solution of Compound B2 (in a solvent such as THF, methanol, DMF, dioxane and the like) is reacted with a base (such as sodium hydroxide, lithium hydroxide, and the like), or a solution of the base (in a solvent such as THF, methanol, DMF, dioxane, water, and the like, or in a mixed solvent) to provide a Compound B3.
Figure imgf000042_0001
Compound B3 is reacted with a solution of a Compound AlO (in a solvent such as DMF, THF and the like) to provide a Compound B4, representative of a compound of formula (I).
EXAMPLE 1
5 -amino-4-(3 -chloro-4-fluoro-pheny lamino)-thieno[2,3 - d]pyrimidine-6-carboxylic acid (3,4-dimethoxy-phenyl)-arnide
(Cpd 3)
Figure imgf000042_0002
DMF (40 mL) was added to a solution of POCl3 (400 ml, 4.4 mol) at 0 0C and the mixture was stirred for 1 hour at ambient temperature. Pyrimidine-4,6-diol Compound Ia (50 g, 0.45 mol) was added to the reaction mixture at RT. After 1 hour, the reaction was heated at reflux for 3 hours. The reaction mixture was concentrated in vacuo to remove the excess POCI3. The resulting residue was diluted with EtOAc and carefully quenched, while stirring, by the slow addition of ice. The isolated organic solution was sequentially washed with an aqueous saturated NaHCθ3 solution and brine. The organic layer was dried over Na2SO4, then filtered and concentrated to give a solid. The solid was extracted with hot hexanes and the solution evaporated down to yield 4,6-dichloro-pyrimidine-5-carbaldehyde Compound Ib (60 g). MS 177 (MH+).
Figure imgf000042_0003
Hydroxylamine hydrochloride (18.0 g, 0.257 mol) in 10% aqueous ethanol (220 mL) was added dropwise to a solution of Compound Ib (39 g, 0.22 mol) in acetic acid (300 TnL). The reaction mixture was stirred for 1 hour at ambient temperature before diluting with EtOAc and washing with water followed by a saturated NaHCCh solution and brine. The organic layer was dried over Na2SO4, then filtered and concentrated to give a solid that upon trituration with hexanes gave 4,6-dichloro-pyrimidine-5- carbaldehyde oxime Compound Ic (44 g). MS 192 (MH+). Note: DSC (differential scanning calorimetry) results of the oxime show a major exothermic decomposition initiating at 85°C.
Figure imgf000043_0001
Compound Ic (16.3 g, 84.9 mmol) was added portionwise with great care to stirring SOCl2 (100 mL) at 00C. After completion of the addition process, and no evidence of exothermic reaction, the reaction mixture was gradually brought to reflux for 3 hours. The reaction mixture was concentrated to remove the excess SOCl2. The residue was diluted in EtOAc, and then concentrated a second time. The resulting solid was triturated with hot hexanes to yield 4,6-dichloro-pyrimidine-5-carbonitrile Compound 1 d (13.9 g). MS ^ 74 (MH ').
Figure imgf000043_0002
3-chloro-4-fluoro-ρhenylamine Compound Ie (15.3 g, 105 mmol) in THF (100 mL) was added dropwise to a solution containing Compound Id (22.0 g, 105 mmol), THF (200 mL) and DIPEA (34 mL, 195 mmol) at 0 0C. After 1.5 hours, the reaction mixture was partitioned between EtOAc and aqueous 10% NH4CI. The EtOAc layer was washed consecutively with aqueous 10% NH4Cl, aqueous IM HCl and water. The organic layer was dried over MgSO4, then filtered and concentrated to a yellow solid. Recrystallization from ether/hexane gave 4-chloro-6-(3-chloro-4-fluoro-phenylamino)- pyrimidinc-5-carbonitrilc Compound If (28.0 g, 95%). MS 283 (MH+).
Figure imgf000044_0001
A solution of 97% mercaptoacetic acid Compound Ig (16 mL, 223 mmol) in pyridine (100 nαL) was added dropwise to a solution of Compound If (60.0 g, 213 mmol) in pyridine (400 mL). After 18 hours, the reaction mixture was partitioned between EtOAc and aqueous IM HCl. The EtOAc layer was washed repeatedly with aqueous IM HCl, then by water and brine. The dried organic layer (MgSO4) was filtered and concentrated to give a brown solid. The solid was suspended in hexane and collected by filtration. The isolated solid [6-(3-chloro-4-fluoro-phenylamino)-5-cyano- pyrimidin-4-ylsulfanyl]-acetic acid Compound Ih required no further purification (53 g, 86%). MS 339 (MH+).
Figure imgf000044_0002
IM potassium t-butoxide (13 mL, 13 mmol) was added dropwise to a solution of Compound Ih (1.48 g, 4.38 mmol) in THF (15 mL) at 0 0C. The reaction was quenched upon completion with IN HCl and diluted with EtOAc. The organic layer was then washed with IN HCl, water, and brine. The collected organic layer was dried over Na2SO4, and filtered and evaporated onto silica gel, then purified by flash chromatography (using an EtOAc/hexane gradient containing 0.1% AcOH) to provide 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6-carboxylic acid Compound Ii (633 mg, 43%) as a brown solid. LC/MS 339, 341 (MH+).
Figure imgf000045_0001
Compound Ii (125 mg, 0.37 mmol) was combined with HATU (140 mg, 0.37 mmol) and DIPEA (80 μl, 0.46 mmol) in THF (3 mL) at room temperature. The mixture was stirred for 5 mins, then 3,4-dimethoxy-phenylamine Compound Ij (63 mg, 0.41 mmol) was added to the reaction mixture. The reaction was complete in less than 30 mins as determined by TLC. The reaction was diluted with IN HCl and extracted into EtOAc. The EtOAc layer was washed sequentially with IN HCl, water and brine, then dried over Na2SO4. The dried solution was filtered and evaporated under reduced pressure, then isolated by reverse phase chromatography (C18 column, CH3CN/H2O/0.05% TFA gradient) to provide Compound 3 (16 mg) as a TFA salt. 1H NMR (400 MHz, CDCl3) δ 8.62 (IH, s), 8.23 (IH, br s), 7.92-7.88 (IH, dd), 7.51-7.44 (IH, m), 7.19 (2H, t), 7.05 (IH, dd), 6.89 (IH, d), 5.69 (2H, br s), 3.94 (3H, s), 3.91 (3H, s). LC/MS 474 (MH+).
Using the procedure of Example 1, other representative compounds of the present invention may be prepared including, but not limited to:
Cpd Name MS (MH+)
1 5-amino-4-(3-chloro-4-iluoro-phenylamino)-thieno[2,3- 444 d]pyrimidine-6-carboxylic acid (4-methoxy-phenyl)-amide
TFA salt
2 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3- 513 d]pyrimidinc-6-carboxylic acid (4-morpholin-4-ylmcthyl- phenyl)-amide TFA salt
4 5-amino-4-(3-chloro-4-fluoro-phcnylamino)-thicno[2,3- 451 d]pyrimidine-6-carboxylic acid (2-morpholin-4-yl-ethyl)- amide TFA salt Cpd Name MS (MH+)
5 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3- 578 djpyrimidinc-θ-carboxylic acid [4-(3-dimcthylamino- propylsυlfamoyl)-phenyl]-amide TFA salt
6 5-amino-4-(3-chloro-4-fluoro-phenylamino)-tliieno[2,3- 506 d]pyriτnidrne-6-carboxylic acid (4-phenoxy-phenyl)-amide
TFA salt
7 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3- 498 d]pyrimidine-6-carboxylic acid (4-trifluoromethoxy-ph.enyl)- amide TFA salt
8 5-amino-4-(3-chloro-4-fluoro-phenylainino)-thieno[2,3- 472 d]pyrimidine-6-carboxylic acid (4-isopropoxy-phenyl)-amide TFA salt
9 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3- 445 d]pyrimidine-6-carboxylic acid (6-methoxy-pyridin-3-yl)- amide TFA salt
10 5-amino-4-(3-chloro-4-fluoro-phenylainmo)-thieno[2,3- 499 d]pyτimidine-6-carboxylic acid (4-morpholin-4-yl-ρhenyl)- amide TFA salt
11 5-amino-4-(3-chloro-4-fluoro-phenylam.ino)-thieno[2,3- 488 d]pyrimidine-6-carboxylic acid 3 ,4-dimethoxy-benzylamide
TFA salt
12 5-amino-4-(3-chloro-4-£luoro-phenylam.ino)-thieno[2,3- 502 d]pyrimidine-6-carboxylic acid [2-(3,4-dimethoxy-ph.enyl)- ethyl]-amide TFA salt
13 5-arnino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3- 511 djpyrimidine-ό-carboxylic acid (4-piperidin-l-ylmethyl- phenyl)-amide TFA salt Cpd Name MS (MH+)
14 5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3- 471 d]pyrimidinc-6-carboxylic acid (4-dimcthylaminomcthyl- phenyl)-amide TFA salt
15 5-amino-4-(3-chloro-4-fluoro-phenylammo)-thieno[2,3- 555 d]pyriτnidine-6-carboxylic acid (4-{2-[rnethyl-(tetrahydro- pyran-4-yl)-amino] -ethyl) -phenyl)-amide TFA salt
16 5 -amino-4-(3 -chloro-4-fluoro-phenylamino)-thieno [2,3- 541 d]pyrimidine-6-carboxylic acid [4-({methyl-[(2i?)-tetrahydro- fαran-2-ylmeth.yl]-amino}-methyl)-phenyl]-amide TFA salt
17 5-aπήno-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3- 541 d]pyrimidine-6-carboxylic acid [4-( {methyl- [(2»S>tetrahydro- furan-2-ylmethyl]-amino}-methyl)-phenyl]-amide TFA salt
18 5-amino-4-(3-chloro-4-fluoro-plienylamino)-thieno[2,3- 526 d]pyrimidine-6-carboxylic acid [4-(4-methyl-piperazin-l- ylτnethyl)-phenyl]-amide TFA salt
EXAMPLE 2
4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-morpholin-4-yl-ethyl)-ainide
(Cpd 19)
Figure imgf000047_0001
A solution of commercially available 4-chloro-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid methyl ester Compound 2a (1.259 g, 5.19 mmol) and 4- fluoro-2-methyl-lH-indol-5-ol Compound 2b (0.779 g, 4.72 mmol) in DMF (18.9 mL) was stirred in an oil-bath at 95 0C for 45 min. The resultant mixture was evaporated in vacuo to dryness. The residue was dissolved in methanol and filtered. The obtained solution was loaded with silica gel and was chromatographically separated (using silica gel with 1 :1 EtOAc and hexanes) to give 4-(4-fIuoro-2-methyl-lH-indol-5-yloxy)~5- methyl-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl ester Compound 2c (0.781 g, 45%) as a brown solid. 1H NMR (300 MHz, (CD3)2CO) δ 10.4 (IH, s, br), 8.55 (IH5 s), 7.20 (IH, d), 7.02 (IH, t), 6.30 (IH, s), 3.82 (3H, s), 3.08 (3H, s), 2.45 (3H, s). MS (ESI) m/z 372 (M+H+).
Figure imgf000048_0001
A solution of Compound 2c (562.5 mg, 1.52 mmol) and LiOH ( 124 mg, 5.18 mmol) in a solvent mixture of 2:1 :1 THFMeOHrH2O (38 mL) was stirred at room temperature overnight. The mixture was acidified with IM HCl to pH 6, was loaded with silica gel and was chromatographically separated (using 10% MeOH and 0.01% HOAc in methylene chloride) to provide 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5- methyl-thieno[2,3-d]pyrirnidine-6-carboxylic acid Compound 2d (504.6 mg, 95%) as a light brown solid. 1H NMR (300 MHz3 (CD3)2CO) δ 9.5 (IH, s, br), 7.25 (IH, s), 5.90 (IH, d), 5.70 (IH, t), 5.00 (IH, s), 1.80 (3H, s), 1.20 (3H, s). MS (ESI) m/z 358 (M+H4).
Figure imgf000049_0001
A solution of Compound 2d (22 mg, 0.062 rnmol), 2-morpholin-4-yl- ethylamine Compound 2e (9.6 mg, 0.074 mmol), HATU (28 mg, 0.074 mmol), and triethyl amine (26 uL, 0.19 mmol) in DMF (1 mL) was stirred at room temperature overnight. The mixture was loaded with silica gel, evaporated in vacuo to dryness, and was chromatographically separated to give Compound 19 as a pink solid (16.4 mg, 57%). 1H NMR (300 MHz, CD3OD) 8 8.48 (IH, s), 7.12 (IH, d), 6.90 (IH, t), 4.10 (2H, m), 3.85-3.60 (6H, m), 3.40 (2H, t), 3.20 (2H, m), 2.92 (3H, s), 2.42 (3H, s). MS (ESI) m/z: 470 (M+H+). Using the procedure of Example 2, other representative compounds of the present invention may be prepared including, but not limited to:
Cpd Name MS (MH4)
20 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl- 532 thieno[2,3-d]pyrimidine-6-carboxylic acid (4-morpholin-4- ylmethyl-phenyl)-amide
21 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl- 468 thieno[2,3-d]pyrimidine-6-carboxylic acid (2-piperidin-l-yl- ethyl)-amide
22 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl- 454 thieno[2,3-d]pyrimidine~6-carboxylic acid (2-pyrrolidin-l- yl-cthyl)-amidc Cpd Name MS (MH+)
23 5-methyl-4-(4-phenoxy-phenylamino)-thieno[2,3- 552 djpyrimidinc-ό-carboxylic acid (4-morpholin-4-ylmcthyl- phenyl)-amdd e
24 4-(4-benzoylamino-phenylainmo)-5-methyl-thieno[2,3- 490 d]pyrirnidine-6-carboxylic acid (2-τnorpholin-4-yl-ethyl)- amide
25 4-(4-benzoylamino-phenylamino)-5-methyl-thieno[2,3- 517 d]pyrimidine-6-carboxylic acid (2-morpholin-4-yl-ethyl)- amide
26 4-(4-benzoylamino-phenylamino)-5-methyl-thieno[2,3- 531 d]pyiimidine-6-carboxylic acid (3-morpholin-4-yl-propyl)- amide
27 4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl- 414 thieno[253-d]ρyrimidine-6-carboxylic acid (2-methoxy- ethyl)-amide TFA salt
Biological Examples
The usefulness of the compounds of the present invention for treating, preventing or ameliorating a chronic or acute kinase mediated disease, disorder or condition was determined using the following procedures. Examples 4-8 are intended as prophetic examples and are expected to demonstrate that said compounds are useful in treating, preventing or ameliorating a chronic or acute kinase mediated disease, disorder or condition as an inhibitor of the indicated kinase.
EXAMPLE 1 EGFR Kinase Assay
The EGFR kinase used was a fusion of Glutathione-S-Transferase (GST) and a PCR amplified intracellular portion of EGFR (NM_005228). The intracellular portion of EGFR started at nucleotide 2189 (corresponding to amino acid 667) and ended at the termination codon. The portion was PCR amplified with primers that added the lambda attB sequences to each end, recombined into an entry vector, then into a GST destination vector (as described in Gateway Technologies Manual by Tnvitrogen Corporation. , Carlsbad, California).
The destination vector was recombined in the DHlOBAC strain of bacteria to produce a bacmid. The bacmid was transfected into Sf 9 cells and the supernatant containing the baculovirus was collected. The GSTEGFR protein was purified using large cultures of Sf 9 cells infected with stock virus. After an appropriate period of time, the cells were collected and lysed. The GSTEGFR was then purified from the lysate on Glutathione-Sepharose columns (as described by Amersham Biosciences, Buckinghamshire, United Kingdom). The EGFR substrate was prepared by biotinylating polyGluTyr (128 mg)
(Sigma , St. Louis, Missouri) in a IX PBS buffer incubated together with a 12-fold molar excess of Sulfo-NHS-LC-Biotin on ice for at least 2 hrs. The free biotin was separated from the biotinylated polyGluTyr on a gel filtration column.
A mixture of a 1OX kinase buffer (500 mM Tris at pH 8.0, 100 mM Magnesium Chloride and 1 mM Sodium Vanadate), DTT (1 mM final from 500 mM stock), ATP (5 uM final from 10 mM stock), biotinylated polyGluTyr (10 μg/μL stock), γ-33P ATP (10 μCi/μL stock) and water was added to each well (90 μL/well) of a Streptavidin Flashplate (Perkin Elmer, Wellesley, MA).
Test compound in 100% DMSO (2 μL) was added to the appropriate wells. Diluted GSTEGFR (1 :300 dilution in 50 mM Tris at pH 8.0 and 0.1% bovine scrum albumin) (10 μL) was added to the wells to initiate the reactions.
The plates were incubated at 30 0C for 1 hr with shaking. The reacted contents were removed and the plates were sequentially washed three times with a IX PBS stop buffer (300 μL without Magnesium and Calcium) and 100 mM EDTA. After the final wash, the same stop buffer (200 μL) was added to the wells. The plates were then sealed and read on the TopCount scintillation counter.
Test compounds were assayed in triplicate at 16 concentrations at half-log dilutions starting at 200 uM. A maximum and minimum signal for the assay was determined on each plate. The percent inhibition of a test compound was calculated according to the formula (max signal - test compound)
(100) = % inhibition
(max signal - min signal)
For a series of test concentrations, the IC50 was derived by graphing percent inhibition against the log of the concentrations tested for a given compound. The IC50 results are shown in Table 1. For those compounds without an TC50, the percent inhibition results are shown at a test concentration of 2 μM.
Table 1 EGFR IC50 (nM)
Cpd IC50 (avg) Cpd IC50 (avg)
1 0.239 10 0.196
2 0.086 11 0.177
3 0.109 12 0.220
4 0.606 13 0.053
5 0.043 14 0.034
6 0.741 15 0.064
7 0.598 16 0.035
8 0.140 17 0.062
9 0.147 18 0.067
19 10%
EXAMPLE 2 VEGF-R2 and A urora-A Screening Assays
A kinase reaction mixture was prepared containing 50 mM Tris-HCl at pH 8, 10 mM MgCl2, 0.1 mM Na3PO4, 1 mM DTT, 10 μM ATP, 0.025 μM biotinylated histone- Hl peptide substrate and 0.2 μCuries per well 33P-γ-ATP (2000-3000 Ci/mmol). 70 μL of the kinase reaction mixture was dispensed into the well of a Strcptavidin FlashPlatc. Test compound stock in 100% DMSO (1 μL) was added to the wells resulting in a final concentration of 1% DMSO in the reaction with a 100 μL final reaction volume. Each enzyme was diluted in 50 mM Tris-HCl pH = 8.0, 0.1% BSA and 30 μL was added to each well to initiate the reaction. The reaction was incubated for one hour at 30 0C. At the end. of the 1 hr incubation, the reaction was terminated by aspirating the mixture from the plate and washing the wells twice with PBS containing 100 mM EDTA. The biotinylated peptide substrate became immobilized on the Flashplate™ and the incorporation of 33P-γ-ATP was measured by reading the plate on a scintillation counter. Inhibition of the enzymatic activity was measured by observing a reduced amount of 33P-γ-ATP incorporated into the immobilized peptide.
The VEGF -R2 enzyme is a fusion protein containing a polyhistidine tag at the N terminus followed by amino acids 786 to 1343 of the rat VEGF-R2 kinase domain (Accession number U93306). The assay used 150 ng of the N-terminal biotinylated peptide biotin-KHKEXAEGSAYEEV-amide (VEGF-R2) per well.
Aurora-A is a fusion protein containing a polyhistidine tag at the N terminus followed by the full length protein encoding the murine Aurora-A (Accession number GB BC014711) expressed and purified from sf9 insect cells. The assay used 400 ng of the N-terminal biotinylated peptide bϊotin-GRTGRRNSΪ-amide (Aurora-A) per well. The IC50 was derived according to the procedure described in Example 1.
Table 2 IC50 (μM)
Cpd VEGF Aurora-A
IC50 (avg) IC50 (avg)
19 0.248 >100
20 0.761 >100
21 0.393 >100
22 0.619 >100
23 >100 >100
24 -100 >100
25 >100 >10
26 >100 >1
27 0.378 >10
EXAMPLE 3
HER-2 Kinase Assay
HER-2 kinase was purified at Proqinase (Freiburg, Germany) from a construct that consisted of a fusion of GST (Glutathione-S-Transferase), HIS6-Thrombin and the nucleotides encoding amino acids 679 to 1255 of HER-2.
A mixture of a 1OX kinase reaction buffer (600 mM Hepes at pH 7.5, 30 mM Magnesium Chloride, 0.03 mM Sodium Vanadate and 500 μig/mL PEG 20,000), DTT (1.2 mM final from a 10 mM stock), ATP (1 μM from a 10 mM stock), biotinylated polyGluTyr (1.5 ng/μL final from stock of 1 μg/μL prepared by Upstate Biotechnologies, Lake Placid, New York), Manganese Chloride (3 mM final from a 1 M stock), γ-33P-ATP (10 μCi/μL stock) and water (70 μL/well) was added to each well of a Streptavidin Flashplate (Cat. # SMP 103, NEN, Boston, MA). Test compound stock (1 μL) was added to the appropriate wells. Diluted
GSTHER2 kinase (6.7 ng/μL diluted into 50 mM Tris-HCl at pH 8.0 and 0.1% bovine serum albumin) (30 μL) was added (total volume of 200 ng/well) to initiate the reactions.
The reaction plates were incubated at 30 0C for 1 hr. The reaction was terminated by aspirating the reaction mixture from the plate wells and washing the wells three times with a 1 X PBS stop buffer (300 μL) and 100 mM EDTA. After the final wash, the same stop buffer (200 μL) was again added to the wells. The plates were then sealed and read on the TopCount scintillation counter. The IC50 was derived according to the procedure described in Example 1. Table 3
HER-2 IC50 (μM) Cpd IC50 (avg)
19 >100
20 >100
21 >100
22 >100
23 >100
24 >10
25 >100
26 >10
27 >10
EXAMPLE 4 c-Src Kinase Assay A mixture of a 1 OX kinase buffer (80 mM MOPS at pH 7.0, 2 mM EDTA and
100 mM Magnesium Chloride), ATP (5 μM final from a 10 mM stock), a Cdc2 peptide KVEKIGEGTYGWYK (100 μM final from a 2.5 mM stock), γ-33P ATP (10 μCi/μL stock) and water (20 μL/wcll) is added to each well of a Streptavidin Flashplate. Test compound in 100% DMSO (0.5 μL) is added to the appropriate wells. Diluted c-Src kinase (human) (Upstate Biotechnology, Lake Placid, New York) (diluted in a buffer consisting of 20 mM MOPS at pH 7.0, 1 mM EDTA, β-mercaptoethanol (0.1%), Brij-35 (0.01%), glycerol (5 %), and 1 mg/mL bovine serum albumin) (2.5 μL) is added to the wells to initiate the reactions. The reaction plates are incubated at 30 0C for 40 min. The reaction is terminated by the addition of a 3% phosphoric acid solution (5 μL). The reaction product (10 μL) is spotted onto a P30 filtermat and washed for 5 minutes in phosphoric acid (75 mM). The wash sequence is repeated two more times, followed with one final wash in methanol. The plates are then dried, sealed and read on the TopCount scintillation counter after adding 30 μL scintillation fluid. Percent inhibition is derived according to the procedure described in Example 1.
EXAMPLE 5 Lyn Kinase Assay A mixture of a 1 OX kinase buffer (50OmM MOPS at pH 7.5 , 1 mM EGTA, 1 mM Sodium Vanadate, 1% β-mercaptoethanol and 100 rnM Magnesium Acetate), ATP (5 μM final from a 10 mM stock), polyGluTyr (0.1 mg/mL final from a 1 mg/mL stock), 7-33P ATP (10 μCi/μL stock) and water (20 μL/well) was added to each well of a Streptavidin Flashplate. Test compound in 100% DMSO (0.5 μL) was added to the appropriate wells.
Diluted Lyn kinase (human) (Upstate Biotechnology, Lake Placid, New York) (diluted in a buffer consisting of 50 mM Tris at pH 7.5, 0.1 mM EGTA, Sodium Vanadate (0.1 mM), β-mercaptoethanol (0.1%) and 1 mg/mL bovine serum albumin) (2.5 μL) was added to the wells to initiate the reactions. The reaction plates were incubated at 30 0C for 40 min. The reaction was terminated by the addition of a 3% phosphoric acid solution (5 μL). The reaction product (10 μL) was spotted onto a P30 filtermat and washed for 5 minutes in phosphoric acid (75 mM). The wash sequence was repeated two more times, followed with one final wash in methanol. The plates were then dried, sealed and read on the TopCount scintillation counter after adding 30 μL scintillation fluid. Percent inhibition was derived according to the procedure described in Example 1. The percent inhibition results are shown in Table 4 at a test concentration of 2 μM. Table 4
Lyn Inhibition (%)
Cpd Inh
19 16%
20 20%
21 8%
22 -2%
23 9%
24 23%
27 23%
EXAMPLE 6 c-^4 W Kinase Assay
A mixture of a 1OX kinase buffer (80 mM MOPS at pH 7.0, 2 mM EDTA and 100 mM Magnesium Acetate), ATP (5 μM final from a 10 mM stock), a peptide EAIYAAPFAKKK (50 μM final from a 0.5 mM stock), γ-33P ATP (10 μCi/μL stock) and water is added to each well (20 μL/well) of a Streptavidin Flashplate. Test compound in 100% DMSO (0.5 μL) is added to the appropriate wells.
Diluted c-Abl kinase (human) (Upstate Biotechnology, Lake Placid, New York) (diluted in a buffer consisting of 20 mM MOPS at pH 7.0, 1 mM EDTA, β-mercaptoethanol (0.1%), Brij-35 (0.01%), glycerol (5 %) and 1 mg/ml bovine serum albumin) (2.5 μL) is added to the wells to initiate the reactions. The reaction plates are incubated at 30 0C for 40 min. The reaction is terminated by the addition of a 3% phosphoric acid solution (5 μL). The reaction product (10 μL) is spotted onto a P30 filtermat and is washed for 5 minutes in phosphoric acid (75 mM). The wash sequence is repeated two more times and is followed with one final wash in methanol. The plates are then dried, sealed and read on the TopCount scintillation counter after 30 μL scintillation fluid is added. The ICso is derived according to the procedure described in Example 1.
EXAMPLE 7 Cell Proliferation Inhibition Assay
The ability of a test compound to inhibit unregulated cell proliferation was determined by measuring incorporation of ' 4C-labelled thymidine into newly synthesized DNA within cell lines derived from carcinomas originating from several tissues. Accordingly, the anti-proliferative effect of a compound on cells with a variety of phenotypes may be determined.
Carcinoma cell lines include those such as HeLa cervical adenocarcinoma (American Type Culture Collection (ATCC), Virginia, Cat. #CCL-2), A375 malignant melanoma (ATCC CRL-1619), SK-OV-3 ovarian adenocarcinoma (ATCC HTB-77), HCT-116 colon carcinoma (CCL-247), PC-3 prostate adenocarcinoma (ATCC CRL- 1435), and MDA-MB-231 (Xenogen Corp.)
The carcinoma cells were trypsinizcd and counted. The cells (3000-8000 count) were added to each well of a 96-well CytoStar tissue culture treated scintillating microplate (Amersham #RPNQ0160) in complete medium (100 μL) and the plate was then incubated in complete medium for 24 hrs at 37 0C in an inert atmosphere containing 5% CO2. Test compound (1 μL) in 100% DMSO was added to the plate test-wells with DMSO only added to control-wells. The plate was incubated in complete medium for a second 24 hr period at 37 0C in an atmosphere containing 5% CO2.
An aliquot of a solution of methyl 14C-thymidine (56 mC/nxmol) (NEN #NEC568 or Amersham #CFA532) and complete medium (20 uL to provide 0.2 μCi/well) was then added to each well and the plate was incubated for a third 24 hr period at 370C in an atmosphere containing 5% CO2. The plate contents were then discarded, the plate was washed twice with PBS (200 μL) and then PBS (200 μ.L) was added to each well. The plate was sealed and the degree of methyl 14C-thymidine incorporation was quantified on a Packard Top Count.
Table 5 Cell proliferation, IC50 (μM)
Cpd HeLa ICso A375 IC50 HCTI I6 IC50
19 >10 >10 >10
20 >10 >10 >10
21 8.5 1.5 9.4
22 15.2 2.2 22.3
23 >10 2.9 7.1
24 >100 >10 >10
25 >10 >10 >10 Cpd HeLa IC50 A375 IC50 HCTl 16 IC50
26 >10 >10 >10
27 >10 >10 >10
EXAMPLE 8
In Vivo Models — Inhibition of Tumor Growth
The ability of a test compound to inhibit unregulated growth of human tumor cells in vivo may be evaluated by implanting human tumor cells into the hindflank of athymic mice, administering a test compound and then quantifying any change in tumor size. Human epidermoid A431 carcinoma cells (106 count) are implanted subcutaneously into the hindflank of female athymic mice (Charles River) and allowed to grow for 6-10 days. After a measurable tumor is established (as determined by baseline caliper measurement), the animal is administered an oral dose of the test compound (in 10% solutol) daily for a period of 30 days. Tumor size is measured every five days and the degree of inhibition is determined by comparing drug-treated animals to vehicle-treated animals.
Variations of this method are intended to include intraperitoneal injection or intravenous infusion as the route of administration and administration of the test compound either alone or in a combination therapy.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and modifications as come within the scope of the following claims and their equivalents.
Throughout this application, various publications arc cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.

Claims

WHAT TS CLATMED TS:
1. A compound of Formula (I)
Figure imgf000059_0001
or a form thereof, wherein
L is selected from the group consisting of NH and O; Ri is selected from the group consisting of aryl-Ra, heteroaryl-Ra, heterocyclyl-Ra, Q-galkyl-Ci-galkoxy, Ci-gaTkyl-aryl-Ra Ci.galkyl-heteroaryl-Ra and Ci-galkyl-heterocyclyl-Ra; Ra is one, two, three or four substituents each selected from the group consisting of hydrogen, halogen, Ci-salkyl, Ci-8alkyl-halo, Ci-salkyl-hydroxy, Ci-gallcoxy, Ci.salkoxy-halo, Ci-salkoxy-hydroxy, amino, Ci_8alkyl-amino, amino-Ci-galkyl, Ci_galkyl-amino-C1_8alkyl, cyano, aryl-Rb, heteroaryl-Rb, heterocyclyl-Rb, Ci-galkyl-aryl-Rb, Ci-salkyl-heteroaryl-Rb, Ci-salkyl-heterocyclyl-Rb, Ci-8alkyl-amino-aryl-RbJ Ci_8alkyl-amino-heteroaryl-Rb, Ci-galkyl-amino-heterocyclyl-Rb, Ci-8alkyl-amino(Ci_8alkyl)-aryl-Rb,
Ci_8aUkyl-amino(Ci-8alkyl)-heteroaryl-Rb, Ci-salkyl-amino^i-salky^-heterocyclyl-Rb, C i -galky 1-amino-C i -salkyl-aryl-Rb , Ci-galkyl-amino-Ci-salkyl-hctcroaryl-Rb, C-i-galkyl-amino-Ci-salkyl-heterocyclyl-Rb,
Ci-galkyl-amino^i-salky^-Ci-salkyl-aryl-Rb, Ci-8alkyl-amino(Ci-salkyl)-Ci-8aUcyl-heteroaryl-Rb, Ci-8alkyl-amino(C1-salkyl)-Ci-8alkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb, sulfonyl-aryl-Rb, sulfonyl-heteroaryl-Rb, sulfonyl-heterocyclyl-Rb, carbamoyl, carbamoyl-Ci-salkyl, sulfonyl-amino, sulfonyl-amino-C i-salkyl, sulfonyl-amino-Ci.galkyl-amino and sulfonyl-amino-C galkyl-amino-Ci-salkyl; Rb is one, two, three or four substituents each selected from the group consisting of Ci-salkyl, Ci-salkoxy, cyano, halo, hydroxy, amino and amino-C i_salkyl;
R2 is selected from the group consisting of aryl-Rc, heteroaryl-Rc and heterocyclyl-Rc;
Rc is one, two, three or four substituents each selected from the group consisting of hydrogen, cyano, halogen, Ci-salkyl, Q-salkyl-halo, C^alkyl-hydroxy, Ci-aalkoxy, Ci-galkoxy-halo, Ci-galkoxy-hydroxy, amino, Ci-galkyl-amino, amino-C i_salkyl, Ci-salkyl-amino-Ci-salkyl, oxyaryl, oxyheteroaryl and amidoaryl; and
R3 is selected from the group consisting of C^alkyl and amino.
2. The compound of claim 1 , wherein L is NH.
3. The compound of claim 1, wherein L is O.
4. The compound of claim 1, wherein Ri is selected from the group consisting of aryl-Ra, heteroaryl-Ra, Ci-salkyl-Ci-salkoxy, Ci_8alkyl-aryl-Ra and
Q.galkyl-heterocyclyl-Ra.
5. The compound of claim 1 , wherein
Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-salkoxy, Ci.8allcoxy-halo, Ci-salkyl-amino-Ci-salkyl, heterocyclyl-Rb, Ci-salkyl-heterocyclyl-Rb,
Ci-8alkyl-amino(Ci.8alkyl)-heterocyclyl-Rb,
Ci-galkyl-amino^i^alky^-Ci-salkyl-heterocyclyl-Rb, oxyaryl-Rb and sulfonyl-amino-Ci-salkyl-amino-Ci-salkyl; and Rb is C1-8alkyl. 6. The compound of claim 1, wherein
R2 is selected from the group consisting of aryl-Rc and hctcroaryl-Rc; and Rc is one or two substituents each selected from the group consisting of hydrogen, halogen, Ci-salkyl, oxyaryl and amidoaryl. A compound of Formula (Ta):
Figure imgf000061_0001
and a form thereof, wherein
Ri is selected from the group consisting of aryl-Ra, heteroaryl-Ra,
Ci-galkyl-aryl-Ra and Ci^alkyl-heterocyclyl-Ra; Ra is one or two substituents each selected from the group consisting of hydrogen, Ci-salkoxy, Ci-salkoxy-halo,
Figure imgf000061_0002
heterocyclyl-Rb, Ci-galkyl-heterocyclyl-Rb,
Ci.galkyl-ammo(Ci-8alkyl)-heterocyclyl-Rb,
Ci-8alkyl-amino(Ci-8alkyl)-Ci_8alkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb and sulfonyl-arnmo-Q-salkyl-arnino-Ci-salkyl; Rb is C-salkyl; Rc is one or two substituents each selected from the group consisting of hydrogen, halogen, Ci-salkyl, oxyaryl oxyheteroaryl and amidoaryl; and R3 is selected from the group consisting of Q^aLkyl and amino. A compound of Formula (Ib):
Figure imgf000061_0003
and a form thereof, wherein
Ra is one or two substituents each selected from the group consisting of hydrogen,
Figure imgf000061_0004
Ci-galkoxy-halo, Ci-salkyl-amino-Ci-gaLkyl, heterocyclyl-Rb, C 1..salkyl-heterocycly 1-Rb ,
Ci-salkyl-amino(Ci-8alkyl)-heterocyclyl-Rb,
Ci_8aIkyl-amino(Ci.8allcyl)-C Lgalkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb and sulfonyl-amino-Ci^alkyl-anoino-Ci-salkyl; and Rb is Ci-βalkyl. 9. A compound of Formula (Ic):
Figure imgf000062_0001
and a form thereof, wherein
R1 is selected from the group consisting of aryl-Ra, heteroaryl-Ra, Ci-galkyl-Ci-galkoxy, d-salkyl-aryl-Ra and Ci-galkyl-heterocyclyl-Ra;
Ra is one or two substituents each selected from the group consisting of hydrogen, Ci_galkoxy, Ci-salkoxy-halo, Ci-salkyl-amino-Ci-salkyl, heterocyclyl-Rb, C i-galkyl-heterocy cly 1-Rb ,
Figure imgf000062_0002
Ci.salkyl-amino^i-galkyO-Ci-salkyl-heterocyclyl-Rb, oxyaryl-Rb, oxyheteroaryl-Rb and sulfonyl-amino-Ci-galkyl-amino-Ci-salkyl; Rb is Ci-salkyl; and Rci and Rc2 is each one or two substituents each selected from the group consisting of hydrogen, halogen, Cx-salkyl, oxyaryl, oxyhctcroaryl and amidoaryl.
10. The compound of claim 1, wherein
L is selected from the group consisting of NH and O;
Ri is selected from the group consisting of 4-OCH3-phenyl.,
3,4-(OCH3)2-phenyI, 4-Sθ2-NH(CH2)3-N(CH3)2-ρhenyl, 4-phenoxy-phenyl, 4-OCF3-phenyl, 4-OCH(CH3)2-phenyl,
6-OCH3-ρyridin-3-yl, (4-morpholin-4-yl)-ρhenyl, (CH2)2-O-CH3, CH2-3 ,4-(OCH3)2-phenyl, (CH2)2-3 ,4-(OCH3)2-phenyl, (4-CH2-ρiperidin-l -yl)-phenyl, [4-CH2-N (CH3)2]-phenyl, {4-(CH2)2-N[(CH3)(tetrahydro-pyran-4-yl)]}-phenyl, {4-CH2-N[(CH3)(CH2-(2i?)-tetrahydro-furan-2-yl)]}-phenyl?
{4-CH2-N[(CH3)(CH2-(2ιS)-tetrahydro-furan-2-yl)]}-ρhenyl, [4-CH2-(4-CH3-piperazin- 1 -yl)]-phenyl, (CH2)2-piperidin- 1 -yl, (CH2)2-pyτroh'din-l -yl, (4-CH2-morpholin-4-yl)-phenyl,
(CH2)2-morpholin-4-yl and (CH2)B -morpholin-4-yl; R2 is selected from the group consisting of 4-F-3-Cl-phenyl,
4-F-2-CH3-indol-5-yl, 4-phenoxy-phenyl and
[4-NHC(O)-phenyl]-phenyl; and
R3 is selected from the group consisting of NH2 and CH3. 11. The compound of claim 1 , selected from:
5 -arnino-4-(3 -chloro-4~fluoro-phenylamino)-thi eno[2,3 -d]pyrimidine- 6-carboxylic acid (4-methoxy-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-morpholin-4-ylmethyl-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (3,4-dimethoxy-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide,
5 -amino-4-(3 -chloro-4-fluoro-phenylamino)-thieno[2,3 -djpyrimidine- 6-carboxylic acid [4-(3-dimethylamino-propylsulfamoyl)-phenyl]- amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-phenoxy-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-trifluoromethoxy-phenyl)-amide,
5 -amino-4-(3 -chloro-4-fluoro-pheny lamino)-thieno [2 ,3 -djpyrimidine- 6-carboxylic acid (4-isopropoxy-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (6-methoxy-pyridin-3-yl)-amide5
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-morpholin-4-yl-phenyl)-amide, 5-amino-4-(3-chloro-4-fluoro-phenylammo)-thieno[2,3-d]pyrimidine- 6-carboxylic acid 3,4-dimeth.oxy-benzylamide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [2-(3,4-dimethoxy-phenyl)-ethyl]-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrinαidine- 6-carboxylic acid (4-piperidin-l-ylmethyl-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-dimethylaminomethyl-phenyl)-amide,
5-amino-4-(3-ch.loro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-{2-[methyl-(tetrahydro-pyran-4-yl)-aminoj- ethyl} -phenyl)-amide,
5-amino-4-(3-chloro-4-fl.uoro-phenylammo)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [4-({methyl-[(2i?)-tetrahydro-furan-2-ylinethyl]- amino} -methyl)-phenyl]-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [4-({methyl-[(21S)-tetrahydro-furan-2-ylmethyl]- amino} -methyl)-phenyl]-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [4-(4-methy 1-piperazin- 1 -y lmethy l)-phenyl] -amide,
4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-morpholin-4-yl-ethyl)-amide,
4 -(4-fluoro-2 -methyl- 1 H-indol-5 -y loxy)-5-methyl-thieno [2,3- d]pyriinidine-6-carboxylic acid (4-morpholin-4-ylmethyl-phenyl)- amide,
4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrirnidine-6-carboxylic acid (2-piperidin-l-yl-ethyl)-amide,
4-(4-fluoro-2-meth.yl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-ρyrrolidin-l-yl-ethyl)-amide; T/US2007/060296
64
5-methyl-4-(4-phenoxy-phenylamino)-thieno[23-d.]pyrimidine-6- carboxylic acid (4-morpholin-4-ylmethyl-phenyl)-amide,
4 -(4-benzoylamino-phenylamino)-5 -methy l-thieno[2 , 3 -d]pyrimidine-6- carboxylic acid (2-morpholin-4-yl-ethyl)-amide,
4-(4-benzoylamino-phenylamino)-5-methyl-thieno[2,3-d]pyrimidine-6- carboxylic acid (2-morpholin-4-yl-ethyl)-amide,
4-(4-benzoylamino-ph.enylam.ino)-5-methyl-thieno[2,3-d]pyrimidine-6- carboxylic acid (3-morpholin-4-yl-propyl)-amide, or
4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-methoxy-ethyl)-amide.
12. The compound of claim 1, selected from:
5 -amino-4-(3 -chloro-4-fluoro-phenylamino)-thieno[2 , 3 -d]pyrimidine-6- carboxylic acid (4-morpholm-4-ylmethyl-phenyl)-amide,
5-arnino-4-(3-chloro-4-fluoro-phenylarnino)-thieno[2,3-d]pyriπiidirie-6- carboxylic acid [4-(3-dirnethylarnino-propylsυ.lfamoyl)-ph.enyl]-arnide,
5-amino-4-(3-chloro-4-fluoro-phenylarnino)-thieno[2,3-d]pyrirnidine-6- carboxylic acid (4-piperidin-l-ylmethyl-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4-dimethylarninornethyl-phenyl)-amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid (4- {2-[methyl-(tetrahydro-pyran-4-yl)-amirio]-eth.yl} - phenyl)-amide,
5 -amino-4-(3 -ch.loro-4-fluoro-phenylamino)-th.ieno[2 , 3 -d]pyrimidine-6- carboxylic acid [4-({metb-yl-[(2i?)-tetrahydro-furan-2-ylmethyl]-amino} - methy l)-phenyl] -amide,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine-6- carboxylic acid [4-( {methyl-[(2)S)-tetrahydro-furan-2-yknethyl]-amino} - methyl)-phenyl]-amide, 5-amino-4-(3 -chloro-4-fluoro-phenylatαin.o)-thieno [2,3 -d]pyrimidine-6- carboxylic acid [4-(4-methyl-piperazin-l-ylmethyl)-phenyl]-amide, or
4-(4-fluoro-2-methyl- 1 H-indol-5-yloxy)-5-methyl-thieno[253- d]pyrimidine-6-carboxylic acid (2-methoxy-ethyl)-amide.
13. The compound of claim 1, selected from:
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-morpholin-4-ylmethyl-phenyl)-amide TFA salt,
5-amino-4-(3-chloro-4-ftuoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [4-(3-dimethylamino-propylsulfamoyl)~phenyl]- amide TFA salt,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4-piperidm-l-ylmethyl-phenyl)-amide TFA salt,
5 -amino-4-(3 -chloro-4-fluoro-phenylamino)-thieno[2,3 -djpyrimidine- 6-carboxylic acid (4-dimethylaminometh.yl-phenyl)-amide TFA salt,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid (4- {2-[methyl-(tetrahydro-pyran-4-yl)-amino]-ethyl} - phenyl)-amide TFA salt,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [4-( {methyl- [(2i?)-tctrahydro-furan-2-y lmcthyl]- amino}-methyl)-phenyl]-amide TFA salt,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [4-({methyl-[(2»S)-tetrahydro-furan-2~y1methyl]- amino}-methyl)-phenyl]-amide TFA salt,
5-amino-4-(3-chloro-4-fluoro-phenylamino)-thieno[2,3-d]pyrimidine- 6-carboxylic acid [4-(4-methyl-piperazin-l-ylmethyl)-phenyl]-amide TFA salt, or
4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-5-methyl-thieno[2,3- d]pyrimidine-6-carboxylic acid (2-methoxy-ethyl)-amide TFA salt.
14. The compound of claim 1 - 13, wherein the compound is an isolated form thereof.
15. A pharmaceutical composition comprising an effective amount of the compound of claim 1 - 13. 16. The pharmaceutical composition of claim 15, wherein the effective amount of the compound is in a range of from about 0.01 mg/kg to about 30 mg/kg of body weight per day.
17. A process for preparing a pharmaceutical composition as claimed in. claim 15 or 16 comprising the step of admixing the compound of claim 1-13 and a pharmaceutically acceptable carrier.
18. A compound as claimed in claim 1 — 13 for use as a medicine.
19. A use of the compound of claim 1- 13 for the manufacture of a medicament for treating, preventing or ameliorating a kinase mediated disease, disorder or condition. 20. A use as claimed in claim 19 wherein the disease, disorder or condition is osteoarthritis, rheumatoid arthritis, synovial pannus invasion in arthritis, multiple sclerosis, myasthenia gravis, diabetes mellitus, diabetic angiopathy, diabetic retinopathy, retinal vessel proliferation, inflammatory bowel disease, Crohn's disease, ulcerative colitis, bone diseases, transplant or bone marrow transplant rejection, lupus, chronic pancreatitis, cachexia, septic shock, fϊbroproliferative and differentiative skin diseases or disorders, central nervous system diseases, neurodegenerative diseases, disorders or conditions related to nerve damage and axon degeneration subsequent to a brain or spinal cord injury, acute or chronic cancer, ocular diseases, viral infections, heart disease, lung or pulmonary diseases or kidney or renal diseases.
21. The use as claimed in claim 20, wherein acute or chronic cancer is selected from bladder cancer, brain, head or neck cancer, breast cancer, colorectal cancer, endometrial cancer, epidermoid cancer, esophageal cancer, gastric cancer, glioma cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, Kaposi's sarcoma, leukemia, lymphoma or papillocarcinoma; and, cancer-associated pathologies selected from abnormal cell proliferation, unregulated cell proliferation, tumor growth, tumor angiopathy, tumor angiogenesis, tumor vascularization or metastatic cancer cell invasion and migration.
22. The use as claimed in claim 20, wherein fibroproliferative and differentiative skin diseases or disorders are selected from papilloma formation, psoriasis, dermatitis, eczema, seborrhea or chemotherapy-induced alopecia; wherein. central nervous system diseases are selected from Alzheimer's disease,
Parkinson's disease or depression; wherein ocular diseases are selected from macular degeneration, diseases of the cornea or glaucoma; wherein viral infections are selected from mycotic infection, autoimmune disease or cytomegalovirus; wherein heart disease is selected from atherosclerosis, neointima formation or transplantation-induced vasculopathies such as arterial restenosis; wherein lung or pulmonary diseases are selected from allergic- asthma, lung fibrosis, pulmonary fibrosis or chronic obstructive pulmonary disorder; and, wherein kidney or renal diseases are selected from acute, subacute or chronic forms of glomerulonephritis or membranoproliferative glomerulonephritis, glomerulosclerosis, congenital multicystic renal dysplasia or kidney fibrosis.
23. The use as claimed in claim 19, wherein the disease, disorder or condition is a HER-2 kinase mediated cancer selected from bladder cancer, brain, head or neck cancer, breast cancer, colorectal cancer, gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, prostate cancer or renal cell cancer.
24. The use as claimed in claim 19, wherein the disease, disorder or condition is an EGFR kinase mediated head or brain cancer in the subject, and wherein the compound penetrates the blood brain barrier. 25. The use as claimed in claim 19, further comprising administering the compound as an adjunct to chemotherapy and radiation therapy.
26. A process for preparing a compound of claim 1 comprising the steps of: a. reacting a compound of Formula Al in a reagent solution to provide a compound of Formula A2 :
Figure imgf000069_0001
reacting the compound of Formula A2 in an acidic solvent with a reagent solution to provide a compound of Formula A3:
Figure imgf000069_0002
A2 A3 reacting the compound of Formula A3 in the presence of a reagent solution to provide a compound of Formula A4:
Figure imgf000069_0003
d. reacting the compound of Formula A4 with a compound of Formula A5 in the presence of a base to provide a compound of Formula A6:
Figure imgf000069_0004
A4 A6 e. reacting the compound of Formula A6 with a compound of Formula A7 in solution with a base to provide a compound of Formula A8:
Figure imgf000070_0001
f. reacting the compound of Formula A8 with a solution of a base to provide a compound of Formula A9:
Figure imgf000070_0002
g. reacting a compound of Formula A9 with, a compound of Formula AlO to provide a compound of Formula Al 1 , representative of the compound of claim 1:
Figure imgf000070_0003
27. A process for preparing a compound of claim 1 comprising the steps of: a. reacting a compound of Formula Bl with a compound of Formula B2 in the presence of a base to provide a compound of Formula B3:
Figure imgf000070_0004
b. reacting the compound of Formula B3 with a base or a solution of a base to provide a compound of Formula B4:
Figure imgf000071_0001
c. reacting the compound of Formula B4 with a compound of Formula AlO to provide a compound of Formula B5, representative of the compound of claim 1 :
Figure imgf000071_0002
PCT/US2007/060296 2006-01-19 2007-01-10 Substituted thienopyrimidine kinase inhibitors WO2007084815A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76023406P 2006-01-19 2006-01-19
US60/760,234 2006-01-19

Publications (2)

Publication Number Publication Date
WO2007084815A2 true WO2007084815A2 (en) 2007-07-26
WO2007084815A3 WO2007084815A3 (en) 2007-12-13

Family

ID=38288338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/060296 WO2007084815A2 (en) 2006-01-19 2007-01-10 Substituted thienopyrimidine kinase inhibitors

Country Status (2)

Country Link
US (1) US20080108611A1 (en)
WO (1) WO2007084815A2 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124083A3 (en) * 2007-04-05 2009-01-15 Amgen Inc Aurora kinase modulators and method of use
WO2009032885A2 (en) * 2007-09-04 2009-03-12 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-d] pyrimidine compounds for treating fibrosis
WO2010103130A2 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
WO2011147753A1 (en) 2010-05-26 2011-12-01 Katholieke Universiteit Leuven, K.U.Leuven R&D Antiviral activity of novel bicyclic heterocycles
JP2012500825A (en) * 2008-08-26 2012-01-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Thienopyrimidine for pharmaceutical composition
WO2012035423A1 (en) 2010-09-15 2012-03-22 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer activity of novel bicyclic heterocycles
CN102725296A (en) * 2010-01-29 2012-10-10 韩美科学株式会社 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
US8404694B2 (en) 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
JP2013520471A (en) * 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4- [Cycloalkyloxy (hetero) arylamino] thieno "2,3-D] pyrimidines having MNKL / MNK2 inhibitory activity for pharmaceutical compositions
JP2013520474A (en) * 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted alkyl group-containing thienopyrimidines for pharmaceutical compositions
JP2013520472A (en) * 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
EP2617435A1 (en) * 2010-09-16 2013-07-24 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
US8513263B2 (en) 2008-10-22 2013-08-20 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US8633201B2 (en) 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
US8697713B2 (en) 2006-07-10 2014-04-15 Boehringer Ingelheim International Gmbh Pyrrolopyrimidines for pharmaceutical compositions
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
US9227975B2 (en) 2008-09-22 2016-01-05 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2B]pyridazine compounds
US9249155B2 (en) 2011-04-01 2016-02-02 Xention Limited Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia
US9493476B2 (en) 2010-05-20 2016-11-15 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
WO2017087608A1 (en) * 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
WO2017096100A1 (en) * 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Heterocycle compounds and uses thereof
WO2017096095A1 (en) * 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
US9682979B2 (en) 2009-07-09 2017-06-20 Array Biopharma, Inc. Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors
US9744176B2 (en) 2012-04-03 2017-08-29 Sanofi Therapeutic uses of novel thienopyrimidine derivatives
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10137127B2 (en) 2016-04-04 2018-11-27 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10370727B2 (en) 2015-10-26 2019-08-06 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
CN110642796A (en) * 2018-06-27 2020-01-03 烟台药物研究所 Quinazoline derivative and application thereof
US10688100B2 (en) 2017-03-16 2020-06-23 Array Biopharma Inc. Macrocylic compounds as ROS1 kinase inhibitors
WO2020212895A1 (en) * 2019-04-16 2020-10-22 Vince Grolmusz Method and apparatus to facilitate the binding of the gap protein to the mutant ras protein by molecular agents to cure ras-mutation related cancers
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology Small molecule modulators of the androgen receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004142A1 (en) * 2001-09-11 2005-01-06 Adams Jerry Leroy Chemical compounds
US20050026935A1 (en) * 2003-06-11 2005-02-03 Xention Discovery Ltd. Compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004142A1 (en) * 2001-09-11 2005-01-06 Adams Jerry Leroy Chemical compounds
US20050026935A1 (en) * 2003-06-11 2005-02-03 Xention Discovery Ltd. Compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633201B2 (en) 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
US8697713B2 (en) 2006-07-10 2014-04-15 Boehringer Ingelheim International Gmbh Pyrrolopyrimidines for pharmaceutical compositions
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US8557816B2 (en) 2007-04-05 2013-10-15 Amgen Inc. Aurora kinase modulators and method of use
US7981891B2 (en) 2007-04-05 2011-07-19 Amgen Inc. Aurora kinase modulators and method of use
WO2008124083A3 (en) * 2007-04-05 2009-01-15 Amgen Inc Aurora kinase modulators and method of use
WO2009032885A2 (en) * 2007-09-04 2009-03-12 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-d] pyrimidine compounds for treating fibrosis
WO2009032885A3 (en) * 2007-09-04 2009-04-30 Epix Delaware Inc Piperidinylamino-thieno[2,3-d] pyrimidine compounds for treating fibrosis
US8404694B2 (en) 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
JP2012500825A (en) * 2008-08-26 2012-01-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Thienopyrimidine for pharmaceutical composition
US8486953B2 (en) 2008-08-26 2013-07-16 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
US9227975B2 (en) 2008-09-22 2016-01-05 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2B]pyridazine compounds
US10590139B2 (en) 2008-09-22 2020-03-17 Array Biopharma Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10011604B2 (en) 2008-09-22 2018-07-03 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9795611B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9796723B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10774085B2 (en) 2008-10-22 2020-09-15 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
US9676783B2 (en) 2008-10-22 2017-06-13 Array Biopharma, Inc. Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
US10047097B2 (en) 2008-10-22 2018-08-14 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US8513263B2 (en) 2008-10-22 2013-08-20 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US10005783B2 (en) 2008-10-22 2018-06-26 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US11267818B2 (en) 2008-10-22 2022-03-08 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US9127013B2 (en) 2008-10-22 2015-09-08 Array Biopharma, Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US9447104B2 (en) 2008-10-22 2016-09-20 Array Biopharma, Inc. Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
US8865698B2 (en) 2008-10-22 2014-10-21 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
WO2010103130A2 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
US10251889B2 (en) 2009-07-09 2019-04-09 Array BioPharm Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US9796724B2 (en) 2009-07-09 2017-10-24 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US9682979B2 (en) 2009-07-09 2017-06-20 Array Biopharma, Inc. Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors
US10758542B2 (en) 2009-07-09 2020-09-01 Array Biopharma Inc. Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors
US9782415B2 (en) 2009-07-09 2017-10-10 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
CN102725296A (en) * 2010-01-29 2012-10-10 韩美科学株式会社 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
US8999973B2 (en) 2010-01-29 2015-04-07 Hanmi Science Co., Ltd Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
CN102725296B (en) * 2010-01-29 2015-04-01 韩美科学株式会社 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
EP2528925A4 (en) * 2010-01-29 2013-07-31 Hanmi Science Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
EP2528925A2 (en) * 2010-01-29 2012-12-05 Hanmi Science Co., Ltd. THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
US8754079B2 (en) 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
US8853193B2 (en) 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
JP2013520471A (en) * 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4- [Cycloalkyloxy (hetero) arylamino] thieno "2,3-D] pyrimidines having MNKL / MNK2 inhibitory activity for pharmaceutical compositions
JP2013520474A (en) * 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted alkyl group-containing thienopyrimidines for pharmaceutical compositions
JP2013520472A (en) * 2010-02-26 2013-06-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
US8648068B2 (en) 2010-02-26 2014-02-11 Boehringer Ingelheim International Gmbh Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
US9840519B2 (en) 2010-05-20 2017-12-12 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US9750744B2 (en) 2010-05-20 2017-09-05 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US9493476B2 (en) 2010-05-20 2016-11-15 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
US10647730B2 (en) 2010-05-20 2020-05-12 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
US9718822B2 (en) 2010-05-20 2017-08-01 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US9902741B2 (en) 2010-05-20 2018-02-27 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
WO2011147753A1 (en) 2010-05-26 2011-12-01 Katholieke Universiteit Leuven, K.U.Leuven R&D Antiviral activity of novel bicyclic heterocycles
WO2012035423A1 (en) 2010-09-15 2012-03-22 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer activity of novel bicyclic heterocycles
EP2617435A1 (en) * 2010-09-16 2013-07-24 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
EP2617435A4 (en) * 2010-09-16 2014-03-12 Univ Osaka Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
US9249155B2 (en) 2011-04-01 2016-02-02 Xention Limited Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia
US10736904B2 (en) 2012-04-03 2020-08-11 Sanofi Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
US10980816B2 (en) 2012-04-03 2021-04-20 Sanofi Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
US10220044B2 (en) 2012-04-03 2019-03-05 Sanofi Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
US9744176B2 (en) 2012-04-03 2017-08-29 Sanofi Therapeutic uses of novel thienopyrimidine derivatives
US10500212B2 (en) 2012-04-03 2019-12-10 Sanofi Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
US10399976B2 (en) 2014-02-03 2019-09-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US11535614B2 (en) 2014-02-03 2022-12-27 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US10807980B2 (en) 2014-02-03 2020-10-20 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US11001583B2 (en) 2014-11-05 2021-05-11 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10813936B2 (en) 2014-11-16 2020-10-27 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10172861B2 (en) 2014-11-16 2019-01-08 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10285993B2 (en) 2014-11-16 2019-05-14 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
US10829448B2 (en) 2015-08-05 2020-11-10 Vitae Pharmaceuticals, Llc Substituted benzoimidazoles as modulators of ROR-γ
US10907215B2 (en) 2015-10-26 2021-02-02 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10655186B2 (en) 2015-10-26 2020-05-19 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10378068B2 (en) 2015-10-26 2019-08-13 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10370727B2 (en) 2015-10-26 2019-08-06 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
WO2017087608A1 (en) * 2015-11-20 2017-05-26 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
EP3868750A1 (en) * 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
US10844074B2 (en) 2015-12-03 2020-11-24 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Heterocycle compounds and uses thereof
AU2016362390B2 (en) * 2015-12-03 2021-11-11 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
WO2017096100A1 (en) * 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Heterocycle compounds and uses thereof
CN108473496B (en) * 2015-12-03 2022-02-01 浙江尖峰亦恩生物科技有限公司 Heterocyclic compounds and their use
CN108473496A (en) * 2015-12-03 2018-08-31 上海亦恩生物科技有限公司 Heterocyclic compound and application thereof
US10829495B2 (en) 2015-12-03 2020-11-10 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
JP2018535980A (en) * 2015-12-03 2018-12-06 チョーチアン チアンフェン−イエン バイオテクノロジー カンパニー リミテッド Thieno-pyrimidine derivatives and uses thereof
WO2017096095A1 (en) * 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
JP2019501889A (en) * 2015-12-03 2019-01-24 シャンハイ イオン ビオテック カンパニー リミテッド Heterocyclic compounds and uses thereof
US10829481B2 (en) 2016-01-29 2020-11-10 Vitae Pharmaceuticals, Llc Benzimidazole derivatives as modulators of ROR-gamma
US10588908B2 (en) 2016-04-04 2020-03-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11191766B2 (en) 2016-04-04 2021-12-07 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11484535B2 (en) 2016-04-04 2022-11-01 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10137127B2 (en) 2016-04-04 2018-11-27 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10668072B2 (en) 2016-04-04 2020-06-02 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
US10688100B2 (en) 2017-03-16 2020-06-23 Array Biopharma Inc. Macrocylic compounds as ROS1 kinase inhibitors
US10966985B2 (en) 2017-03-16 2021-04-06 Array Biopharma Inc. Macrocyclic compounds as ROS1 kinase inhibitors
US11186573B2 (en) 2017-07-24 2021-11-30 Vitae Pharmaceuticals, Llc Inhibitors of ROR gamma
US10913739B2 (en) 2017-07-24 2021-02-09 Vitae Pharmaceuticals, LLC (121374) Inhibitors of RORγ
CN110642796A (en) * 2018-06-27 2020-01-03 烟台药物研究所 Quinazoline derivative and application thereof
WO2020212895A1 (en) * 2019-04-16 2020-10-22 Vince Grolmusz Method and apparatus to facilitate the binding of the gap protein to the mutant ras protein by molecular agents to cure ras-mutation related cancers

Also Published As

Publication number Publication date
US20080108611A1 (en) 2008-05-08
WO2007084815A3 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
WO2007084815A2 (en) Substituted thienopyrimidine kinase inhibitors
US7427625B2 (en) Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
US8013153B2 (en) Substituted pyrimidine kinase inhibitors
US7605154B2 (en) Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7855205B2 (en) Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US8314234B2 (en) Bicyclic pyrimidine kinase inhibitors
TWI601718B (en) 2-arylaminopyridines, pyrimidine or triazine derivatives, processes for preparing the same, and uses thereof
WO2007081630A2 (en) Substituted pyrimidinyl kinase inhibitors
WO2006130673A1 (en) 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
WO2007047646A2 (en) Substituted dihydro-isoindolones useful in treating kinase disorders
US20080293785A1 (en) Substituted benzothiazole kinase inhibitors
US7659284B2 (en) Thiazolopyridine kinase inhibitors
US7579356B2 (en) Thia-tetraazaacenaphthylene kinase inhibitors
US8367825B2 (en) Substituted pyrimidinyl oxime kinase inhibitors
US7638518B2 (en) Substituted pyrazole kinase inhibitors
US20090111810A1 (en) Substituted pyrimidine-5-carboxamide and 5-carboxylic ester kinase inhibitors
AU2018289939B2 (en) Heterocyclic compound
US7893064B2 (en) Hydrazone derivatives as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07701218

Country of ref document: EP

Kind code of ref document: A2